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Summary
This thesis describes work carried out to characterise cardiac responses to cannabinoids. 
A particular focus of the work was to study the mechanism by which cannabinoids 
protect hearts from ischaemia-reperfusion injury
Studied in rat isolated right atria, anandamide (an endocannabinoid) induced a limited 
positive chronotropy. As this response was blocked by indomethacin and not mimicked 
by methanandamide (a non-hydrolysable analogue), the mechanism of action appears to 
involve conversion and release of products of cyclooxygenase-2. Conversely, negative 
chronotropy was observed when baseline rate was elevated by a fi-adrenoceptor agonist. 
The pharmacological profile of this anti-adrenergic response indicated the involvement 
of CB2 receptors.
Potential protection afforded by cannabinoids against rat isolated hearts subjected to 
ischaemia-reperfusion was studied in two different models. In the first, hearts were 
subjected to global, no-flow ischaemia-reperfusion with agonists introduced 5 min 
before ischaemia. The second method subjected hearts to regional ischaemia- 
reperfusion with agonists introduced 35 min into ischaemia. Antagonists, where used, 
were present throughout the protocol.
In the global, no-flow ischaemia-reperfusion model both anandamide and 
methanandamide significantly reduced infarction but in the regional ischaemia- 
reperfusion model only methanandamide significantly reduced infarction. In both 
models the infarct limiting action was lost in the presence of both the CBi receptor
antagonist SR141716A and the CB2 receptor antagonist SR144528. However, CBi- or 
CB2-receptor agonists, used alone or in combination, were ineffective at reducing 
infarct size. These results suggest that neither CBi nor CB2 receptors, alone or in 
synergy mediate cardioprotection. These results suggest that one or more novel sites of 
action, possibly a new cannabinoid receptor subtype, might mediate cardio-protection in 
rat hearts.
These findings demonstrate the potential for cannabinoids to be used as adjuncts to 
thrombolytics. However, the in vivo effects of cannabinoids in situations of 
compromised cardiac function needs to be assessed as they could potentially cause 
excessive hypotension due to peripheral vasodilatation.
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1.0 Introduction
Myocardial infarction, caused by coronary artery occlusion resulting in impaired blood 
supply (ischaemia), is a leading cause of morbidity and mortality in the western world. 
Although the incidence varies according to region, it is estimated that 147,000 men and
121.000 women of all ages suffer myocardial infarction each year in the UK (Petersen 
etal., 2004).
1.1 Ischaemic injury
Myocardial cells gain their energy through glucose and fatty acid oxidation and oxygen- 
independent glycolysis (Theroux, 1999). During ischaemia the oxidative pathways are 
impaired which causes an increase in the rate of anaerobic glycolysis. Under these 
conditions, the hydrolysis of ATP derived from glucose metabolism becomes a 
significant source of hydrogen ions (Lopaschuk et al.9 1993). ATP hydrolysis is not the 
only mechanism to contribute to the acidosis seen during ischaemia. Protons can also 
be formed from carbon dioxide retention, NADH and hydrogen ion accumulation 
resulting from glutamate oxidation and from fatty acid recycling, however, it is 
debatable as to how much they contribute to hydrogen ion build up (Dennis et al., 
1991). The accumulation of hydrogen ions leads to the activation of the 
sodium/hydrogen exchange system which results in hydrogen ion removal from the cell 
in exchange for sodium resulting in cell swelling (Theroux, 1999). Activation of the 
sodium/potassium ATPase may also occur resulting in a decrease in intracellular 
sodium ion concentration, however, a low intracellular ATP level along with a low pH 
(both caused by the hydrolysis of ATP) are not favourable conditions for the 
functioning of the ATPase and therefore this exchange mechanism may not have a great
9
effect on lowering the intracellular sodium ion concentration (Van Emous et al., 1998). 
Another system exchanging intracellular sodium for extracellular calcium which is 
stimulated by the abnormally high intracellular levels of sodium ions assists the 
sarcoplasmic reticulum in maintaining calcium ion homeostasis (Hasenfuss et al., 1999; 
Tani & Neely, 1989). This further results in calcium overload, sarcolemmal bleb 
formation and rupture of the cell ultimately resulting in cell death (Theroux, 1999). 
Figure 1.1 summarises the consequence of acidosis induced by ischaemia and the 
mismatch between rates of glucose oxidation and glycolysis during reperfusion.
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Figure 1.1 Diagram showing the cascade o f events leading to the increase in calcium caused by 
ischaemia. Glycolysis is increased while glucose oxidation is impaired resulting in an increase in 
hydrogen ions. The sodium/hydrogen exchange system (NHE-l) activated by high intracellular levels of 
hydrogen ions tries to compensate by exchanging hydrogen ions for sodium ions. The subsequent 
elevated intracellular levels o f sodium ions activate the sodium/potassium ion (Na/K*) ATPase but this 
is inhibited due to increased cellular ATP hydrolysis and a low pH. As the elevated intracellular levels of 
sodium ions are not adequately controlled by the Na+/h f ATPase, sodium ions are exchanged for 
extracellular calcium ions via the sodium/calcium ion exchanger i.e. in reverse o f its normoxic function. 
Extracellular calcium ion influx via this route contributes to the overall calcium ion overload observed in 
ischaemia-reperfusion injury.
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1.2 Reperfusion injury
Ischaemic myocardium will ultimately die if it is not reperfused. Reperfusion, 
restoration of flow after a period of ischaemia is currently the only means of salvaging 
ischaemic myocardium and limiting infarct development providing reperfusion occurs 
soon after occlusion (Yellon et al., 1999). Although reperfusion is necessary, it is 
associated with additional injury processes, including contractile dysfunction 
(stunning), the development of arrhythmias, endothelial dysfunction and cell death 
collectively leading to a decrease in cardiac performance (Black, 2000; Park & 
Lucchesi, 1999; Piper et al., 1998; Yellon & Baxter, 1999). Many mechanisms have 
been shown to contribute to reperfusion injury including oxygen free radical formation, 
calcium overload and neutrophil mediated myocardial and endothelium injury amongst 
others (Wang et al., 2002). These mechanisms will be discussed individually in the 
following section.
The generation of oxygen free radicals (highly reactive species containing unpaired 
electrons) including the superoxide anion, hydroxyl radical and hydrogen peroxide, is a 
key process in the development of reperfusion injury. Reintroduction of oxygen at the 
onset of reperfiision results in the release of these free radicals and along with the 
ischaemia-induced decrease in antioxidant activity leaves the myocardium at risk of 
damage. Ultimately these oxygen free radicals react with cellular phospholipids and 
proteins resulting in the disruption of the membrane ultrastructure and dysfunction of 
cellular proteins (Wang et al., 2002).
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Calcium overload also causes problems during reperfusion, where intracellular calcium 
concentrations increase rapidly due to sodium influx into the cells (Bueike et al., 1999). 
Calcium overload not only results from the activation of exchanger processes but also 
due to calcium gaining access through ‘leaky* myocardial cells which have occurred as 
the result of morphological changes in the cellular structure i.e. cell swelling and 
disruption of the tissue lattice. A dysfunctional sarcoplasmic reticulum which has 
become damaged as a result of the generation of oxygen-derived free radicals and is 
unable to adequately sequester and store intracellular ionized calcium can also 
contribute to increased calcium levels (Park & Lucchesi, 1999).
Calcium overload has been found to contribute in several ways to reperfusion injury. At 
reoxygenation calcium induces excess myofilament activation and in addition causes an 
increase in mitochondrial calcium resulting in impairment of the mitochondria’s ability 
to generate ATP therefore limiting metabolic recovery of the cell. Calcium activated 
proteases may also destroy intracellular structures (Wang et a l, 2002).
Although the inflammatory response is needed for healing and scar formation, it is also 
another process contributing to myocardial reperfusion injury. Neutrophils, a major 
cellular component of this process, not only gain access through extravasation into the 
endothelium but also by releasing proteases, pro-inflammatory mediators, oxygen 
metabolites and other cytotoxic substances which result in an increase in tissue injury 
(Frangogiannis et a l, 2002; Hansen, 1995; Jordan et al, 1999).
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Myocardial stunning is mechanical dysfunction, which persists after reperfusion, despite 
the absence of irreversible damage and in spite of restoration of the coronary flow. 
There are two hypotheses for this phenomenon, one being calcium overload and the 
other that oxygen-derived free radicals interact with cell membranes and essential 
proteins resulting in the alteration of membrane structures and dysfunction of various 
cellular proteins, leading to decreased function and reversible tissue injury (reviewed by 
Bolli & Marban, 1999). Recovery from stunning could be due to slow repair of 
oxidative damage and/or resynthesis of contractile proteins or reversal of intracellular 
Ca2+ overload. The two theories for stunning are not mutually exclusive and could both 
play a role in this process (reviewed by Bolli & Marban, 1999).
When nutrient and oxygen supply is restored to the cells as a result of reperfusion the 
cytosolic calcium ion concentration is still high. This can have a harmful effect in that 
an uncontrolled, excessive force may be generated resulting in hypercontraction which 
is sustained shortening and stiffening of the myocardium resulting from changes in 
intracellular calcium concentrations (Moens et al., 2005). Inhibition of the contractile 
machinery during the first stage of energy recovery can prevent hypercontracture 
because it allows time for the cation concentrations to be corrected (Piper et al., 1998). 
Correcting the cytosolic pH can also influence hypercontracture. The cytosolic pH is 
lowered during ischaemia due to anaerobic metabolism and the breakdown of ATP, 
producing an excess of hydrogen ions. The pH of the interstitial fluid is rapidly 
normalised upon reperfusion creating a gradient between that and the cytosol. This 
results in the activation of the sodium/hydrogen ion exchange system, which corrects 
the acidosis (Piper et al., 1998). However acidosis has been shown to be a protective
14
feature and can inhibit the myofibrillary machinery therefore helping to prevent 
hypercontracture. This protection was demonstrated when ischaemic rabbit 
myocardium was reperfused with erythrocyte containing perfusate which was either 
acidotic (pH 6.6) or that contained 5-(N, N-dimethyl)-amiloride a sodium/hydrogen 
exchange system inhibitor. Reperfiision with either resulted in a marked decrease in 
cell death (Kaplan et al., 1995; Piper et al., 1998; Wang et al.9 2002).
Survivors of the initial ischaemia-reperfusion injury (the combined damage caused by 
ischaemia and reperfiision) are susceptible to remodelling (hypertrophy and change in 
shape) of the heart, which can lead to heart failure. Myocardial remodelling is a 
reversible process triggered by mechanical stretch. In the case of myocardial infarction, 
remodelling is asymmetric and related to infarct expansion, which is as a result of death 
and slippage of cardiomyocytes. Remodelling of the area as a result of expansion 
causes an increase in left ventricular mass, volume and shape (Swynghedauw, 1999). 
Figure 1.2 demonstrates the effect of remodelling over time.
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Figure 1.2 Diagram o f remodelling. Arrows indicate forces induced by intraventricular pressure.
Arrows indicate intraventricular forces induced by contraction that cause stretching and thinning o f the 
infracted area. Neurohumoral stimulation due to impaired contractile function stimulates hypertrophic 
growth o f  the whole heart resulting in cardiac hypertrophy.
1.3 Interventions for cardiac damage
Besides early reperfiision, ischaemia-reperfusion injury can be reduced by a number of 
different interventions. Ischaemic preconditioning, first documented by Murry et al. 
(1986), is a powerful way of reducing the severity of ischaemia-reperfusion injury by 
subjecting the heart to a series of sub lethal ischaemic episodes. This phenomenon can 
be mimicked by numerous pharmacophores including adenosine (Mubagwa & Flameng, 
2001) and opioids for example morphine and bradykinin B2-receptor agonists (Schultz 
& Gross, 2001). Unfortunately, the clinical application of this experimental finding is 
limited as the treatment needs to be applied before a coronary artery becomes occluded 
and most patients are asymptomatic before suffering their first heart attack (Moens et 
al., 2005). Another phenomenon known as postconditioning which is defined as brief 
periods of reperfiision alternating with re-occlusion applied during the early stages of 
reperfusion also reduces infarct size (Penna et a l , 2006; Zhao & Vinten-Johansen,
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2006). Two clinical studies (Staat et al., 2005; Warren, 2005) in patents undergoing 
percutaneous coronary intervention showed that postconditioning was a safe and 
efficient cardioprotective intervention however, more extensive studies need to be 
conducted.
At present there are no clinical interventions targeting ischaemia-reperfusion injury 
apart from reperfusing the affected area soon after occlusion. Thrombolytics (‘clot 
busting’ drugs) are the group of drugs used as the standard treatment (Department of 
Health, 2000). As mentioned, there is experimental evidence to suggest that ischaemia- 
reperfusion injury can be limited through treatment. However, suggested treatments 
either have to be given before occlusion (e.g. preconditioning) or they can have a 
detrimental effect on those patients with compromised cardiac function (e.g. adenosine). 
Therefore there is a need to develop agents that can reduce ischaemia-reperfusion injury 
when provided as adjuncts to thrombolytics without significantly impairing contractile 
function.
Cannabinoids are a group of drugs, which have come to light recently as having 
influence on the cardiovascular system, with evidence suggesting a role in protection 
against ischaemia-reperfusion injury (Joyeux et al., 2002; Lagneux & Lamontagne, 
2001). Cannabinoids are the active constituents of marijuana {cannabis sativa plant), 
greater than 60 of which have been discovered. The most abundant cannabinoid is A9- 
tetrahydrocannabinol, and it is this, which gives marijuana its psychotropic effects 
(Mechoulam et al., 1998; Sugiura & Waku, 2002).
17
One of the most important developments in cannabinoid research was the discovery, in 
1992, of the first endogenous cannabinoid agonist Af-arachidonoylethanolamide 
(anandamide, Figure 1.3).
b a
Figure 1.3 Structure ofanandamide. Anandamide consists o f (a) a polar ethanolamide head group
and (b) a hydrophobic arachidonoyl chain (Khanolkar & Makriyannis, 1999).
The discovery of anandamide (Devane et a l, 1992) came at a similar time to that of the 
identification and cloning of the two cannabinoid receptors designated cannabinoid 
receptor 1 and 2 (CBi and CB2 respectively; Matsuda et a l, 1990; Munro et al., 1993).
1.4 Synthesis and metabolism of the endogenous cannabinoid anandamide
Two hypotheses have been suggested for anandamide biosynthesis. The first involves 
the activation of phospholipase A2 and D respectively followed by the release of 
arachidonic acid and ethanolamine. Anandamide would be formed by anandamide 
synthase creating an amide bond. However, there is a flaw with this theory in that 
concentrations that would be required are in excess of those found physiologically 
(Devane & Axelrod, 1994; Kruszka & Gross, 1994). The second and more widely 
accepted hypothesis is one where acyltransferase changes the conformation of 
arachidonic acid by moving the position of the donor phospholipid to create an amide 
bond at the ethanolamide head group in the third position of the
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phosphatidylethanamide. Activation of phospholipase D would then result in the 
formation of anandamide (Cadas et al., 1997; Sugiura et a l, 1996a; Sugiura et al., 
1996b).
5 /1-I Arachidonyl-phospholipid Phosphatidylethanolamine
N-acyltransferase
N-acylphosphatidyl ethanolamide
Phospholipase D Phosphatidic acid
Anandamide
Figure L4 Biosynthesis o f anandamide from arachidonic acid. Increases in intracellular calcium 
cause a conformational change in arachidonic acid from the sn 1 position o f an N-acylphospholipid to 
the amide group o f the Phosphatidylethanolamine. Phospholipase D then cleaves a phosphodiester bond 
to create anandamide (Cadas et al., 1997; Felder & Glass, 1998).
1.5 Uptake and degradation of endocannabinoids
Termination of the biological actions of anandamide appears to be a two step process, 
the first being transportation into the cell and secondly once inside the cell enzymatic 
hydrolysis by anandamide amidohydrolase, latterly known as fatty acid amide 
hydrolase. Fatty acid amide hydrolase is an intracellular, membrane-bound enzyme,
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which is the primary enzyme responsible for the hydrolytic breakdown of anandamide 
into arachidonic acid and ethanolamine (Deutsch et al., 2002; Khanolkar & 
Makriyannis, 1999). Fatty acid amide hydrolase has a similar distribution to CBi 
receptors in the central nervous system and it is shown to work in conjunction with 
other membrane proteins to facilitate anandamide transport by creating an inward 
concentration gradient as a result of anandamide metabolism (Deutsch et al., 2001; 
Egertova etal., 1998).
For anandamide to be metabolised by fatty acid amide hydrolase it must be transported 
into the cell. There are a number of theories by which anandamide uptake is thought to 
occur. The first is that anandamide is transported across the plasma membrane by a 
carrier protein (Hillard & Jarrahian, 2000). However, this theory is still controversial as 
this putative anandamide transporter has yet to be cloned. The second theory is that of 
simple diffusion where the fatty acid amide hydrolase-mediated cleavage of anandamide 
maintains a concentration gradient (Glaser et al., 2003). The third hypothesis is that 
cellular components such as protein or lipid compartments can sequester anandamide 
(Hillard & Jarrahian, 2003). And the fourth theory is that anandamide can be 
internalised by a calveolae-mediated endocytic process (McFarland et al., 2004). It is 
also possible that all these mechanisms exist.
Anandamide can also be metabolised by cyclooxygenase-2 (COX-2; but not COX-1), 
which is an inducible form of cyclooxygenase leading to the generation of a number of 
oxygenated products including PGE2-ethanolamide (Yu et al., 1997). However, the 
physiological significance of this pathway has yet to be discovered. Using
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indomethacin (inhibitor of COX-2), can prevent biosynthesis into prostaglandin (Kozak 
& Mamett, 2002; Mechoulam et al., 1998; Pertwee & Ross, 2002; Yu et al., 1997).
Lipoxygenase mediated hydroxylations of anandamide analogues to those of 
arachidonic acid have also been reported (Burstein et a l, 2000). Anandamide has been 
shown to be metabolised to hydroperoxyeicosatetraenoyl ethanolamides which like the 
hydroperoxyderivatives of arachidonic acid act as TRPV1 (transient receptor potential 
vanilloid 1 cation channel, formally known as the vanilloid VR1 receptor) agonists 
(Craib et al., 2001) and to hydroxyl-eicosatetraenoylethanolamides which have been 
shown to have similar affinity for both CBi and CB2 receptors as anandamide itself 
(Edgemond et al, 1998). However, the biological significance of lipoxygenase 
metabolism of cannabinoids is unclear.
Uptake inhibitors such as A-(4-hydroxyphenyl)arachidonylamide (AM404) have been 
developed (Beltramo et a l, 1997). This agent was discovered while studying the 
structure-activity relationships of anandamide, where it was found that by substituting 
the 2-hydroxyethyl group in anandamide with a 4-hydroxyphenyl group resulted in a 
competitive transport inhibitor i.e. it blocks the effects of both the anandamide 
transporter (Beltramo et al, 1997; Khanolkar & Makriyannis, 1999) and fatty acid 
amide hydrolase (Jarrahian et al., 2000). One problem with the use of this antagonist is 
that it can act as a TRPV1 agonist (Zygmunt et a l, 2000). However, AM404 can be 
used in conjunction with the TRPV1 antagonist, capsazepine, to exclude potentially 
confounding actions mediated by TRPV1 activation. Other transport inhibitors have 
since been developed including VDM 11 an anandamide membrane inhibitor which has
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little or no activity at TRPV1 receptors and is also an inhibitor of fatty acid amide 
hydrolase (De Petrocellis et al., 2000; Vandevoorde & Fowler, 2005), OMDM-2 an 
inhibitor of anandamide cellular uptake which does not cross react with fatty acid amide 
hydrolase (Qrtar et a l, 2003) and UCM707 an uptake inhibitor which has no affinity for 
fatty acid amide hydrolase, TPRV1, CBi or CB2 receptors (Lopez-Rodriguez et a l, 
2003). As some of these inhibitors do not affect fatty acid amide hydrolase they 
provide further evidence that an anandamide transporter does exist.
Inhibitors have also been developed which prevent the hydrolysis of anandamide. 
These include palmitoylisopropylamide which is a fatty acid amide hydrolase inhibitor 
(Jonsson et al., 2001) and methyl arachidonyl fluorophosphate which is an irreversible 
anandamide amidase inhibitor (Deutsch et al., 1997). The effect of these inhibitors 
would be to decrease both the inward concentration gradient created by the hydrolysis 
of anandamide by fatty acid amide hydrolase and to decrease the efficiency of 
anandamide clearance (McFarland & Barker, 2004). These inhibitors would have 
therapeutic benefit over other ligands as they would act in a site and event specific 
manner.
1.6 Cannabinoid receptors
In the 1990’s two cannabinoid receptors designated cannabinoid receptor 1 and 2 (CBi 
and CB2 respectively) were identified and cloned (Matsuda et al., 1990; Munro et al., 
1993). The locations of these receptors have been established through the use of 
quantitative autoradiography, in situ hybridisation and immunocytochemistry (Howlett 
et a l, 2002). CBi receptors were found to be widely distributed throughout mammalian
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tissues with the greatest expression levels being in the nervous system. They were also 
found to a lesser extent in peripheral tissues including the heart, lungs and bone 
marrow. CB2 receptors on the other hand were found to be expressed predominantly in 
immune tissues including the spleen, tonsils and lymph nodes. CB2 mRNA has also 
been found to be expressed in several types of leukocytes including macrophages, 
monocytes, B lymphocytes and natural killer cells (Felder & Glass, 1998; Galiegue et 
a l ,1995; Howlett, 2002; Sugiura & Waku, 2002; Valk et a l, 1997).
The homology of cannabinoid receptors has also been investigated and revealed that the 
CB2 receptor has only a 44% homology with the CBi receptor (Felder & Glass, 1998). 
However, the homology of CBi receptors across species (human, rat and mouse) is 
highly conserved with 97 to 99% amino acid identity. CB2 receptors are more divergent 
with mouse CB2 gene clones having only 82% overall identity with the human CB2 
receptor (Chakrabarti et al, 1995; Shire et a l, 1996).
The use of agonist stimulation resulted in the discovery that responses mediated by 
cannabinoid receptors were due to their being coupled to G-proteins indicating they are 
members of the G-protein coupled receptor superfamily (Howlett et al, 2002). Figure
1.5 summarises intracellular signalling pathways known to be coupled to cannabinoid 1 
receptor activation.
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Plant-derived cannabinoids
Synthetic cannabinoidsEndogenous cannabinoids
N, P/Q 
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cAMP Ca'
PKB PKA
Control of cell function
Figure 1.5 Cannabinoids exert their effects by binding to specific Gj/0-protein-coupled plasma 
membrane receptors. The cannabinoid 1 receptor (CB]) signals several different pathways including 
inhibition o f adenyfyl cyclase (AC), modulates ion channels (inhibits N- and P/Q type voltage sensitive 
calcium channels (VSCC), activates G-protein-activated inwardly rectifying potassium channels (GIRK), 
and activates mitogen- and stress-activated protein kinase cascades (ERK, JNK, p38), and protein kinase 
B (PKB), all resulting in control o f cell function by cannabinoids. The cannabinoid 2 receptor couples to 
some but not all if the pathways shown (see review Howlett et al., 2002).
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In general, CBi and CB2 receptors couple to Gy0 receptors (Howlett et al., 2002). 
However, under conditions where Gi/0 is inactivated by treatment with pertussis toxin, 
the CBi receptor has also been shown to interact with Gs proteins. Evidence that CBi 
receptors couple to Gs has been provided from investigations into the relationship 
between CBi receptors and D2 (dopamine) receptors (Glass & Felder, 1997; Jarrahian et 
al., 2004). In striatal neurones in primary culture activation of either CBi or D2 
receptors resulted in the inhibition of cyclic AMP accumulation whereas simultaneous 
activation of the receptors resulted in an augmentation of cyclic AMP accumulation. 
Pertussis toxin treatment (used to block Gi) of the neurones prevented the inhibition of 
adenylate cyclase by both the CBi and D2 receptors and uncovered a CBi but not D2 
receptor-mediated stimulation of cyclic AMP. This response was blocked by 
SR141716A (CBi receptor antagonist now known as rimonobant) providing an 
alternative CBi receptor signalling pathway (Glass & Felder, 1997). A further study has 
demonstrated that CBi receptor activation inhibits cyclic AMP accumulation in the 
absence of D2 receptors, whereas CBi-stimulated cyclic AMP accumulation (through 
Gs) occurs in their presence. This Gs subunit switching was not prevented in the 
presence of pertussis toxin and occurred in the presence and absence of D2 receptor 
activation (Jarrahian et al., 2004).
The orphan G-protein-coupled receptor GRP55 has more recently come to light as a 
new cannabinoid receptor (Sawzdargo et al., 1999). GRP55 has been shown to bind 
and be activated by endogenous (anandamide), natural (abnormal cannabidiol) and 
synthetic (CP55940) cannabinoid ligands. Therefore, GPR55 has been classed as a
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novel cannabinoid receptor and a biological and pharmaceutical target of cannabinoid 
ligands (Drmota, 2004).
Other recent evidence supports the idea that cannabinoids can mediate responses 
through receptors other than CBi and CB2 receptors. A novel endothelial cannabinoid 
receptor has been proposed on the basis of functional pharmacology but has yet to be 
cloned (Jarai et al., 1999). Abnormal cannabidiol, a plant-derived cannabinoid, is a 
selective agonist (Jarai et al., 1999; Offertaler et al., 2003) and 0-1918 is a selective 
antagonist (Offertaler et al., 2003) of this receptor. Cannabinoid responses in CBi^' and 
CB2^ ‘ mice are thought to be due to activation of this potentially novel cannabinoid 
receptor (Jarai et al., 1999; Offertaler et al., 2003).
It has also been found that some cannabinoids are full agonists of TRPV1. 
Cannabinoids have been shown to produce similar inward currents to those of capsaicin 
and the responses to these cannabinoids are sensitive to the capsaicin antagonist, 
capsazepine (Bevan et al., 1992; Di Marzo et al., 1998; Smart & Jerman, 2000; 
Zygmunt et al., 1999).
There are a number of reports that cannabinoid responses may be mediated by receptors 
other than those previously described. Of interest to the current work, anandamide 
responses in the heart have been shown to be sensitive to both SR141716A and 
SRI44528 (CBi and CB2 receptor antagonists respectively) but insensitive to agonists 
selective for CBi or CB2 receptors, either alone or in combination (Ford et al., 2002).
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On the basis of these findings, the authors suggested that there may be a novel 
cannabinoid site of action in the heart.
In addition to direct interaction with extracellular receptors, cannabinoids can be taken 
up into cells and metabolised to products of the arachidonic acid cascade such as 
prostaglandins, thromboxane and leukotrienes (Belton & Fitzgerald, 2003; Ellis et al., 
1995; Kozak et al., 2002). These pathways can be circumvented by the use of 
methanandamide a non-hydrolysable analogue of anandamide (Abadji et al., 1994) and 
through the use of uptake inhibitors including OMDM-2 (Ortar et al., 2003) and 
UCM707 (Lopez-Rodriguez et al., 2003) and inhibitors of fatty acid amidase hydrolase 
including palmitoylisopropylamide (Jonsson et al., 2001) and methyl arachidonyl 
fluorophosphates (Deutsch et al., 1997).
1.7 Cannabinoid receptor ligands
The elucidation of the structure of anandamide has led to the development of several 
agonists with CBi- or CB2-selectivity. CBi-selective agonists include R-(+)- 
methanandamide a non-hydrolysable analogue of anandamide (Abadji et al., 1994), 
arachidonlycyclopropylamide and arachidonyl-2 ’ -chloroethylamide more commonly 
known as ACPA and ACEA respectively (Hillard et al., 1999) which are more selective 
than anandamide itself which is an agonist of both CBi and CB2 receptors as well as 
acting as a full agonist of TRPV1 (Di Marzo et al., 1998; Smart & Jerman, 2000; 
Zygmunt et al., 1999). CB2-selective agonists which include 3-(l ’ 1 *dimethylbutyl)-1 - 
deoxy-A8-THC (Huffman et al., 1999) more commonly known as JWH-133, HU-308 
(Hanus et al., 1999), L-759656 and L-759633 (Ross et al., 1999) are derived from
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modifications to the tetrahydrocannabinol molecule (Hanus et al., 1999; Huffman et al., 
1999). Table 1.1 shows a comparison of the binding affinities of agonists for the classic 
cannabinoid receptors.
Table 1.1: Comparison o f the affinities (Kd o f cannabinoid ligands for the classic cannabinoid
receptors.
Cannabinoid Lisand I CBi 1 CBi | Reference
Agonists
Anandamide 71.7nM 279nM (Hillaid etal., 1999)
Methanandamide 20nM (Abadji et al., 1994)
ACEA 1.4nM >2000nM (Hillard etal., 1999)
ACPA 2.2nM 715nM (Hillard et al., 1999)
JWH-133 677nM 3.4nM (Huffman et al., 1999)
HU-308 >10mM 22.7nM (Hanus et a l, 1999)
AM281 12nM 4200nM (Lan et al., 1999)
L-759656 4888nM 11.8nM (Ross eta l, 1999)
L-759633 1043nM 6.4nM (Ross etal., 1999)
Antagonists
SR141716A 11.8nM 13200nM (Felder eta l, 1998)
SR144528 437nM 0.6nM (Rinaldi-Carmona et a l, 1998)
AM630 5152nM 31.2nM (Ross eta l, 1999)
LY320135 141nM 14900nM (Felder et al, 1998)
Antagonists of both CBi and CB2 receptors have also been developed. The first were 
SR141716A and SR144528, which are selective for CBi and CB2 receptors, 
respectively (Rinaldi-Carmona et al., 1995; Rinaldi-Carmona et al., 1998). However, it 
is now apparent that these two antagonists can also act as inverse agonists (MacLennan 
et al., 1998; Rinaldi-Carmona et al., 1998) whereby they produce opposing effects to 
those observed with agonists. This could be the result of antagonism of endogenously 
released endocannabinoids, however some of these effects have been produced in the 
absence of any cannabinoid release (Pertwee, 2005). Analogues of SRI 41716A which 
include AM281 (Lan et al., 1999) and AM251 (Gatley et al., 1996) have also been 
shown to block the CBi receptor. Another CBi antagonist LY320135 has also been
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developed (Felder et al, 1998) but this compound has less affinity than SR141716A for 
CBi receptors. LY320135 has also been shown to bind to muscarinic and 5 -HT2 
receptors in the low micromolar range (Felder & Glass, 1998) and it can behave as an 
inverse agonist at CBi receptors (Pertwee, 2005). 6-iodopravadoline (AM630; 
Hosohata et al, 1997) is a selective CB2 receptor antagonist and as with all the 
antagonists discussed it also acts as an inverse agonist (Ross et al, 1999). This 
antagonist can also behave as a weak partial agonist at CBi receptors (Ross et al, 
1999). Table 1.1 shows a comparison of the binding affinities of antagonists for the 
classic cannabinoid receptors.
Responses can be pharmacologically distinguished with the use of selective agonists 
and antagonists and also with the use of transgenic mice which have been developed. 
These mice can be either CBi or CB2 deficient or lack both of the receptors; therefore 
the responses produced can be definitively associated or discounted from cannabinoid 
receptor involvement.
1.8 Signal transduction
Cannabinoid receptors have been shown to couple to a number of signal transduction 
pathways. Table 1.2 lists a few of these pathways. Some of the pathways activated by 
cannabinoids are thought to be involved in influencing survival and apoptotic pathways. 
Activation of phosphatidylinositol 3-kinase and protein kinase B (Aikawa et al, 2000) 
have been shown to mediate the inhibition of ischaemia/reperfusion-induced cardiac 
apoptosis (in the form of infarction) induced by insulin (Jonassen et al, 2001). It is 
possible that cannabinoids limit apoptosis through this pathway as CBi receptors are
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also coupled to phosphatidylinositol 3-kinase and protein kinase B activation (Gomez 
del Pulgar et al., 2000). Supporting a role of cannabinoids in influencing both survival 
and pro-apoptotic pathways is the finding that the endocannabinoid, anandamide has 
been shown to be both anti- and pro-apoptotic (Maccarrone et al., 2000b). Anandamide 
was shown to inhibit apoptosis through a receptor sensitive to both SR141716A and 
SRI44528 and induce apoptosis through TRPV1 activation in human neuroblastoma 
and lymphoma cells (Maccarrone et al., 2000b).
Table 1.2: Cannabinoid receptor-coupled signalling transduction pathways
Receptor Signalling target Effect References
CB} Adenylate Cyclase Inhibition (Felder etal., 1993) 
(Wade et al., 2004)
p38 MAPK Stimulation (Derkinderen et al., 2001)
p42/44 MAPK Stimulation (Bouaboula et al., 1995) 
(Derkinderen et al., 2003)
PB/protein kinase B Stimulation (Sanchez et al., 1998) 
(Galve-Roperh et al., 2002)
Voltage-operated calcium channels
N-type Inhibition (Pan etal., 1996) 
(Wilson et al., 2001)
P/Q type Inhibition (Twitchell et al., 1997) 
(Hampson et al., 1998)
L-type Inhibition (Gebremedhin et al., 1999) 
(Straiker et al., 1999)
Potassium channels
G-protein-coupled inwardly rectifying 
potassium channel
Stimulation (McAllister et al., 1999) 
(Robbe et al., 2001)
h Stimulation (Hampson et al., 1995) 
(Mu etal., 2000)
Id Inhibition (Mu etal., 1999)
Im Inhibition (Schweitzer, 2000)
CB* Adenylate Cyclase Inhibition (Bayewitch et al., 1995)
P42/44 MAPK Stimulation (Bouaboula etal., 1996)
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1.9 Biological activity of cannabinoids
As previously stated anandamide acts as a full agonist at TRPV1 (Zygmunt et al., 
1999). Activation of these channels results in a vasodilator response and the induction 
of apoptosis in neuronal and immune cells (Jeon et al., 1996; Maccarrone et al., 2000a; 
Zygmunt et al., 1999).
Cannabinoids have been shown to be able to inhibit macrophage activity (Bumette- 
Curley et al., 1993; Tang et al., 1993). Macrophages play an important part in local 
host defence mechanisms by recognising, phagocytosing, and destroying the foreign 
agent. Anandamide and 2-arachidonyl-glyceryl have been shown to be synthesised by 
macrophages (Di Marzo et al., 1999; Di Marzo et al., 1996; Kozak et al., 2000; 
Pestonjamasp & Burstein, 1998; Varga et al., 1998) which have also been shown to 
express both CB2 and to a lesser extent CBi receptors (Bouaboula et al., 1993; Galiegue 
et al., 1995). Although cannabinoids are well established immune modulators their 
physiological relevance is still unclear.
1.10 Cardiovascular effects of cannabinoids
The most prominent component of the cardiovascular action of exogenous cannabinoid 
administration is prolonged hypotension (a triphasic response) and bradycardia. When 
a bolus of anandamide was injected into rats it resulted in a transient, vagally mediated 
bradycardia associated with a fall in blood pressure (phase I) which was followed by a 
brief pressor response (phase II) and a more prolonged decrease in blood pressure 
(phase ID; (Varga et al., 1995). Figure 1.6 shows a trace of this triphasic effect.
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Figure 1.6 Typical trace showing effect in rats o f an intravenous injection o f anandamide (lmg/kg)
on diastolic blood pressure and heart rate (beats/minute, BPM). Arrows indicate drug application 
(Malinowska et al., 2001).
Investigation of this triphasic effect found that phase I was due to activation of the 
TRPV1 as the selective TRPV1 antagonist capsazepine (Bevan et al., 1992) reduced the 
response to anandamide and methanandamide (a stable analogue of anandamide). Phase 
HI was found to be a result of CBi receptor activation because SR141716A abolished 
the effect caused by both anandamide and methanandamide (Malinowska et al., 2001). 
Both the effects in phase HI were absent in CBi receptor knockout mice further 
confirming that CBi activation caused this effect (Jarai et al., 1999). The mechanism 
behind the brief vasopressor response (phase II) is unknown although this response was 
not inhibited by either capsazepine or SR141716A therefore there is a lack of both 
TRPV1 and CBi involvement (Lake et al., 1997; Malinowska et al., 2001).
In isolated rat hearts, Ford et al. (2002) showed that anandamide and methanandamide 
could significantly reduce coronary perfusion pressure, which is indicative of coronary 
vasodilatation. Left ventricular developed pressure, a measure of workload/muscle 
function was also reduced. Responses to anandamide were sensitive to both 
SR141716A and SR144528 but could not be explained by synergistic activation of both
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CBi and CB2 receptors. Therefore it was concluded that in the rat heart responses to 
anandamide were mediated via one or more novel sites.
In the 1970’s iV-acylethanolamine (anandamide) was shown to accumulate in infarcted 
dog hearts (Epps et al., 1979) demonstrating that cannabinoids accumulate under 
pathological conditions. This could be because cannabinoids are retaliatory metabolites 
which are released in response to injury to limit tissue damage. It is therefore not 
surprising that cannabinoids have been found to be cardioprotective with endogenous 
cannabinoids being shown to mediate cardiac preconditioning (see 2.2.4a-c) induced by 
lipopolysaccharide, where SR144526 (but not SR141716A) was shown to abolish the 
protective effect of pre-treatment with lipopolysaccharide providing evidence of a CB2 
mediated effect (Lagneux & Lamontagne, 2001).
Endocannabinoids are also thought to directly protect against ischaemia-reperfusion 
injury with sn-2 arachidonyoylglycerol (another endogenous cannabinoid) and 
palmitoylethanolamide but not anandamide improving myocardial recovery, decreasing 
levels of biochemical markers (creatine kinase, lactate dehydrogenase) associated with 
ischaemic injury and reducing infarct size (Lepicier et al., 2003). This protective 
mechanism was attributed to the activation of the CB2 receptor as the response to sn-2 
arachidonyoylglycerol was blocked by SR144528 and only partially blocked by 
SR141716A. It was also concluded that this protection involved the activation of signal 
transduction factors including p38, ERK1/2 and protein kinase C activation.
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The cannabinoids anandamide and 2-arachidonoyl glycerol have been shown to be 
generated in monocytes and platelets following a myocardial infarction. CBi receptor 
inhibition was shown to prevent hypotension but decreased the 2 hour mortality rate 
from 70% in control animals to 36% in those treated with SR141716A (Wagner et al., 
2001a). This means that cannabinoids are important at the time of infarction because of 
their vasodilatory effect and ability to alter cytokine production (Klein et al., 2000) and 
during the recovery process where vasodilation caused by the cannabinoids helps to 
maintain tissue perfusion when there is decreased cardiac output and compensatory 
sympathetic vasoconstriction (Wagner et al., 2001a).
1.11 Current applications of cannabinoid use
Marijuana has been used for thousands of years as a therapeutic and recreational drug. 
Its therapeutic potential was documented as early as the 4th century BC when a Chinese 
emperor was using Marijuana to treat malaria, constipation and rheumatic pains (Felder 
& Glass, 1998).
In Western Europe, cannabis is the most used illicit drug. However, no deaths have 
been attributed to its use either recreationally or therapeutically probably because acute 
toxicity of cannabinoids is very low. Cannabis use does have adverse effects including 
sedation, psychological effects (anxiety, panic), physical effects (muscle weakness, 
tachycardia and hypotension) and impairment of psychomotor and cognitive 
performance (Kumar et al., 2001).
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Recently cannabinoid use in adolescence has been linked to an increased risk of 
psychosis. A number of studies have been conducted which have found that the use of 
cannabis is associated with an increased risk of psychosis or psychotic episodes 
(Andreasson et al., 1987; Arseneault et al., 2002; Caspi et al., 2005; Fergusson et al., 
2005; Henquet et al., 2005; van Os et al, 2002). These studies not only compared 
cannabis users to non-cannabis users but some also looked at the effects of increasing 
cannabis use which again resulted in an associated increased risk of psychosis 
(Andreasson et al., 1987; Fergusson et al., 2005; van Os et al., 2002).
Although there are adverse effects related to the use of cannabis, cannabis also has 
therapeutic applications. These are due to receptors (CBi predominantly) being located 
in the central and peripheral nervous system and include treatment of spastic disorders 
including multiple sclerosis. There is much anecdotal evidence from multiple sclerosis 
sufferers that cannabis relieves their symptoms such as spasticity, tremors and pain. 
One study used a chronic relapsing allergic encephalomyelitis mouse model to 
investigate the effects of cannabinoids on an experimental model of multiple sclerosis 
(Baker et al., 2000). It was found that the cannabinoid agonists, WIN 55,212, 
tetrahydrocannabinol, methanandamide and JWH-133 tonically controlled both 
spasticity and tremor and that CBi and CB2 cannabinoid antagonists exacerbated these 
effects. It has been suggested that this exacerbation is due to the inhibition of a 
tonically active, endogenous control mechanism (Baker et al., 2000).
Clinical trials of cannabinoid based medicines for the treatment of multiple sclerosis 
have been conducted however; the results were inconclusive with participants reporting
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feeling improvements that could not be confirmed by tbe study physicians. Therefore 
based on the studies to date, it is the opinion of the National Multiple Sclerosis Society's 
Medical Advisory Board, that there is currently insufficient data to recommend 
marijuana or its derivatives as a treatment for multiple sclerosis. However, in Canada a 
cannabis-derived drug, Sativex, is licensed for the treatment of pain associated with 
multiple sclerosis. The approval of the license was based on a four-week clinical trial 
conducted in 66 people with multiple sclerosis (Rog et al., 2005). However, Sativex has 
not been licensed in the United States and GW Pharmaceuticals who developed this 
drug are currently conducting a clinical trial to evaluate it as a treatment for spasticity.
Cannabinoids have been indicated for anti-emetic use. Anti-emetic drugs are 
administered before and after chemotherapy when nausea and vomiting are frequent. At 
present dronabinol (tetrahydrocannabinol capsules) or the synthetic analogue nabilone 
(tetrahydrocannabinol in sesame oil) are approved for this use. Although the common 
side-effect (drowsiness) is problematic (Guzman, 2003; Kumar et al, 2001).
Cannabinoids have been shown to have analgesic effects but in a review of controlled 
trials by (Campbell et al., 2001), it was concluded that a single dose of cannabinoid was 
no more effective than codeine in treating nociceptive pain and that there was not 
enough evidence to suggest introducing cannabinoids into clinical practice for the 
treatment of pain. This was reinforced by an investigation into the use of dronabinol, in 
which patients with chronic refractory neuropathic pain did not have any benefit from 
the therapy (Attal et al., 2004). However, it was suggested that the route of 
administration of cannabinoids may be a major factor in any future therapies as it is
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known that tetrahydrocannabinol undergoes variable absorption in the gut (Kumar et al., 
2001) therefore getting the dosage for the individual right may be difficult.
It is the effects, which cannabinoids elicit on the cardiovascular system, in particular 
protecting the heart from injury, which has prompted this study. The aims of the study 
are to characterise cannabinoid-induced cardioprotection and investigate the 
mechanisms by which this protection is mediated. It is hoped that these studies will 
shed light on whether cannabinoids might be effectively used as adjuncts to 
thrombolytics to reduce ischaemia-reperfiision injury associated with heart attacks.
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2.0 General Methods
2.1 Animals and animal husbandry
Male Wistar rats weighing 250-300g at purchase were group housed, in numbers up to 
five, in standard plastic polypropylene rat cages (35cm x 55cm approximately). The 
ambient room temperature was 19-23°C, in accordance with Home Office Code of 
Practice regulations, and the rats were maintained under a 12:12 h, light: dark 
photoperiod (8am - 8pm light). The rats were allowed free access to a standard rodent 
maintenance diet and drinking water. Animal care and procedures were according to 
the Animals (Scientific Procedure) Act, UK, 1986.
2.2 Preparation of isolated right atria
Male Wistar rats (300-350g) were killed with an overdose of sodium pentobarbital (i.p., 
0.2g/kg, Sagatal; Rhone Merieux, Harlow, UK). The skin was incised by a longitudinal 
cut from the middle of the abdomen to the throat. The abdomen was then opened up to 
the diaphragm. The diaphragm was cut away from the ribs. The thorax was cut open 
on the left and right sides of the rib cage, starting at the diaphragm and proceeding to 
the first rib. The complete anterior thoracic wall was then removed to expose the heart.
Right atria were removed, complete with the sino-atrial node, using threads tied to the 
superior vena cava, which attached the tissue to an isometric force transducer. Two 
threads, one attached to the inferior vena cava and the other attached to the 
atrioventricular junction, were used to secure the preparation to a stainless steel support. 
A resting tension of approximately lg was applied. Right atrial preparations were 
allowed to beat spontaneously.
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The tissue was suspended in 20ml tissue baths containing Krebs bicarbonate solution 
maintained at 37 ± 0.5°C by a Grant W6 circulator (Cambridge, UK) and continuously 
bubbled with a gas mixture of 95% 02/5% CO2 . The Krebs bicarbonate solution was 
made up with deionised water and had the following composition (mM): NaCl (118.4); 
KC1 (4.7); CaCl2.2H20  (2.5); MgS04.7 H20  (1.2); NaHC03 (24.9); KH2P04.2H20  
(1.2); glucose (11.6). All salts were obtained from Fisher Scientific (Leicestershire, 
UK).
The tensions developed by the right atrial preparations were measured by Dynamometer 
UF1 Isometric Force Transducers linked to a Grass pre-amplifier model 7P17 Driver 
Amplifier (Astro-Med Inc, West Warwick, USA) connected to a PC using an 
ADInstruments PowerLab 4/20 analogue digital converter (Oxfordshire, UK). Tension 
development and heart rate were continuously displayed and recorded on a PC.
An equilibration period of approximately 30 minutes was allowed before any 
experimental protocol commenced. During this period the tissue was washed every 10 
minutes with fresh Krebs bicarbonate solution.
2.3 Langendorff buffered-perfused rat hearts
Male Wistar rats (300-350g) were killed with an overdose of sodium pentobarbitone 
(i.p, 0.2g/kg, Sagatal; Rhone Merieux, Harlow, UK) and heparinized (100 U kg-1 i.p, 
CP Pharmaceuticals, Wrexham, UK) to prevent the formation of blood clots in the 
heart. The abdomen was opened up to the diaphragm by making a longitudinal cut from 
the middle of the abdomen to the throat. The diaphragm was then cut from the ribs and
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the thorax was cut open on the left and right sides of the rib cage, starting at the 
diaphragm and proceeding to the first rib. The ribcage was then removed to expose the 
heart. The heart and lungs were then removed together and immersed in a beaker of 
ice-cooled Krebs bicarbonate solution.
Hearts were cannulated within 90 seconds of excision and perfused at a constant 
pressure of 80mmHg (Langendorff perfusion, Figure 2.1) with perfusate consisting of a 
modified Krebs bicarbonate solution (NaCl 118 mM, KC1 4.7 mM, KH2PO4 1.2 mM, 
MgS04 1.2 mM, 2.5 mM Ca2+, 11 mM glucose, 100 mU/1 insulin). Care was taken not 
to insert the cannula too far into the aorta, which would occlude the coronary ostia or 
damage the aortic value. To prevent air bubbles from accumulating in the cannula, the 
perfusion fluid was allowed to flow through the cannula prior to contact with the aorta 
(leaving a drop on the tip of the cannula) and through use of a bubble trap at the top of 
the cannula. The heart was temporarily held in place by an aorta clip while the lungs 
and other connective tissues were removed from the heart. The aorta was then securely 
attached to the glass cannula using a cotton thread. A small incision was then made in 
the pulmonary artery to facilitate drainage of coronary perfusate and remnants of tissue 
(trachea, lung or connective tissue) were removed. The left atrium was removed to 
accommodate the placement of a pressurized (5-15 mmHg) balloon inserted into the left 
ventricle, connected to a pressure transducer (Ohmeda, model P23XL-1), which was 
further connected to a Grass pre-amplifier model 7P1G (Astro-Med Inc, West Warwick, 
USA). Coronary flow was measured by ultrasonic flow probes (Transonic H4X) 
connected to a Transonic Systems Inc small animal blood flow meter model T206 
(Transonic Systems Inc, Ithaca, New York, USA). Electrical activity was continuously
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recorded by means of two stainless steel needles inserted into the ventricular apex and 
base, connected to an electrocardiograph amplifier (Grass EKG Tachograph pre­
amplifier model 7P4F, Astro-Med Inc, West Warwick, USA). Where electrical pacing 
was applied, hearts were electrically stimulated at 5Hz with square wave pulses of 5ms 
duration at a voltage of threshold + 10% via bipolar platinum electrodes placed on the 
surface of the heart. Depending on the protocol, some hearts were allowed to beat 
spontaneously as indicated in the relevant sections.
Hearts were immersed in 100ml organ baths containing perfusate maintained at 37°C ± 
0.5°C by a Grant W6 circulator (Cambridge, UK). The perfusate was continuously 
bubbled with a gas mixture of 95% 0^5%  CO2 . Salts were obtained from Fisher 
Scientific (Leicestershire, UK) and insulin (stock concentration of lOOOu/L) was 
obtained from LEO Pharma (Ballerup, Denmark).
All parameters (left ventricular developed pressure, heart rate and coronary flow) were 
continuously recorded using a PowerLab 800 (ADInstruments, Oxfordshire, UK) and 
digitally stored on a PC. Rate pressure product was calculated as the left ventricular 
developed pressure (mmHg) x heart rate (bpm).
Two protocols for the constant pressure Langendorff perfusion system were used in this 
study. Firstly, a no-flow global model of ischaemia (4.2) was used. In this model 
global ischaemia is induced by clamping the inflow line and the heart reperfused by 
releasing the clamp. The second model is that of regional ischaemia (5.2). In this
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model, an area of the heart is made ischaemic by tying a snare around the left anterior 
descending coronary artery. The heart is reperfused by releasing the snare.
95% 0 2 +  5 % C 0 2
A ir stone for distribution 
o f  95/5%  0 2/C 0 2.
Pressurised balloon m easuring left 
ventricular developed pressure
Drug infusion point
Rate set to 10% o f  coronary flow
Electrodes connected
to a bioam p for the measurement
o f  the heart’s electrical activity
t
Heart chamber
Figure 2.1 The Langendorff constant pressure heart perfusion system. All parts o f the apparatus
are water-jacketed with warm circulating water to maintain the temperature o f the perfusate and the 
heart at 37°C.
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2.4 Assessment of perfusion methodology for identifying cardioprotective 
responses 
2.4a Protocol
The methodology and protocols used to assess cardioprotection were validated by 
conducting a series of experiments to precondition the hearts. Preconditioning is where 
the heart is exposed to one or more sequences of sub-lethal ischaemic insult and 
reperfusion that protects the myocardium and vascular endothelial cells against 
functional damage and cell death caused by a more severe prolonged period of 
ischaemia that would normally be associated with a degree of cell death (see section 1.3 
for a more detailed description). This phenomenon has previously been shown to cause 
a robust cardioprotection in different models of ischaemia-reperfusion injury across 
many species including man (Riksen et al., 2004). The protocol used for the 
preconditioning experiments is shown in Figure 2.2 with hearts subsequently being 
stained with a 1% solution of triphenyltetrazolium chloride (see section 4.2 for a more 
detailed description of the staining technique).
Preconditioning Ischaemia Reperfusion
I I I I
5 5 5 5 5 5 5 30 120
Time (min)
Figure 2.2 Preconditioning protocol. There are three brief intermittent periods o f ischaemia 
(filled boxes) and reperfusion (open boxes) before a prolonged period o f ischaemia.
2.4b Results
The results from the preconditioning experiments showed that preconditioning 
significantly improved recovery of left ventricular developed pressure but not coronary 
flow above that of the control group (Figure 2.3a and b). Preconditioning also 
significantly reduced infarct size from 28 ± 3% to 16 ± 6% (of the whole heart, Figure 
2.3c). The effect on heart rate was not assessed because hearts were paced to 300 beats 
per minute.
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Figure 2.3 Assessment o f the effect ofpreconditioning on rat isolated Langendorff-perfused hearts 
subjected to 30 min global, no-flow ischaemia and 2 hour reperfusion. A. Effect o f preconditioning on 
left ventricular developed pressure (LVDP). B. Effect o f preconditioning on recovery o f coronary flow 
(CF). C. Effect o f preconditioning on infarct sue. * represents P<0.05 using unpaired Student’s t-test.
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2.4c Discussion
The results seen in the validation study show that the methodology and protocols used 
in this report are justified as preconditioning was shown to protect the heart. Although 
the cardioprotection seen was significant it was not to the same extent as previous 
studies which have seen a decrease from an infarct of 29.4% of the area at risk in 
control hearts to 7.3% in preconditioned hearts, however, dogs were used in those 
experiments whereas rats where used here and hearts were subjected to four 5 minute 
episodes of ischaemia whereas in the current study, hearts were subjected to three 5 
minute episodes (Murry et al.9 1986). Thus it is possible that differences in animals 
and methodologies may account for the disparity in infarct size reduction observed.
2.5 Global versus regional ischaemia
The main difference between the global and regional ischaemia models is the damage 
which is caused. In regional ischemia, the tissue is damaged by the lack of oxygen, by 
mechanical stress, and by the consequences of a low-flow condition caused by collateral 
flow whereas in global ischemia the lack of oxygen is the only cause of cellular injury 
(Schaper, 1980).
There are few clinical situations where hearts are subject to global no-flow ischaemia. 
Global no-flow models of ischaemia are mainly limited to cardiac transplantation and 
cardiac surgery where the aorta is cross-clamped, whereas regional ischaemia models 
try to replicate the most common clinical manifestation of cardiac ischaemia, which 
occurs during myocardial infarction. In this case an occlusion occurs in a coronary
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blood vessel resulting in disruption of blood supply to an area of the myocardium and 
reperfusion is instigated through the use of thrombolytic drugs or primary angioplasty. 
The regional ischaemia model is the closest to the most common clinical situation 
(myocardial infarction). However, this model does have its own drawbacks in that the 
clinical manifestation of regional ischaemia is associated with underlying 
pathophysiologies such as atherosclerosis, which are not present in the experimental 
method. In addition, reperfusion would be considerably slower in the clinical situation 
than in the mechanical model due to the time it would take for the clot to be broken 
down by the thrombolytics, although a faster reperfusion might be obtained with 
primary angioplasty. Although the extent of damage and initial condition of the hearts 
may differ between the experimental model and the clinical situation, the mechanisms 
are likely to be similar. Thus, treatments effective at reducing ischaemia-reperfusion 
damage experimentally would be likely to do the same in the clinical situation.
The global model gives a maximal area at risk {i.e. the whole heart) therefore it is a 
good model to use initially as potential changes in infarct size will be easier to detect. It 
could also be said that the global model could represent the area at risk of a larger 
animal i.e. that of a human and would therefore be more relevant to the clinical 
situation. However, there is the problem in that it is difficult to administer drugs only at 
reperfusion due to a lack of certainty that coronary flow is uniform across the whole 
heart. This means that the best time for drug administration is before ischaemia at which 
time it is impossible to distinguish between a preconditioning type of response and a 
direct cardioprotective response. It has previously been suggested that any stress to a
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heart for example repeated episodes of angina could induce a preconditioning-like state 
(Murry etal., 1986).
Many different models have been proposed to evaluate ischaemia-reperfusion injury 
with their overall aim to mimic the clinical situation. However, as you move away from 
the study of human tissue the model becomes less relevant to the human condition 
(Figure 2.5 demonstrates this issue).
Investigative Technique
Human Hearts in vivo
Large mammalian hearts in vivo
Small mammalian hearts in vivo
Isolated perfused hearts
Isolated muscle preparations
Isolated cells
Relevance
Figure 2.5 Diagram showing the clinical relevance o f different investigative techniques. The 
Langendotff perfused heart method has been highlighted to demonstrate its bearing (adapted from 
(Hearse & Sutherland, 2000).
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Chapter 3
Pharmacological evaluation of cannabinoid 
responses in isolated tissue preparations taken 
from rat hearts.
Table of Contents
3.1 Introduction 50
3.2 Experimental Protocol 53
3.21 Agonist studies 53
3.22 Antagonist studies 53
3.3 Drug preparation 53
3.4 Statistical analysis 54
3.5 Results 55
3.51 Studies in naive isolated right atria 55
3.51a Agonists Studies 55
3.51b Antagonist Studies 55
3.52 Studies using isoprenaline-treated isolated right atria 56
3.52a Agonist Studies 56
3.52b Antagonist Studies 57
3.6 Discussion 68
49
3.1 Introduction
Cannabinoids, including the endogenous camiabinoid anandamide, have been shown to 
elicit numerous effects on the heart both in vitro and in vivo. However, the results from 
these studies have been inconsistent when the effects of eannabinoids on heart rate have 
been studied.
Using isolated perfused hearts, it was found that plant derived eannabinoids such as A9- 
tetrahydrocamiabinol and caimabinol cause tachycardia whereas cannabidiol caused 
bradycardia (Smiley ei a l , 1976). Few studies have determined the direct effects of 
eannabinoids on isolated tissue preparations of the heart.
Oilier studies have investigated the effect of eannabinoids on force of contraction in 
electrically stimulated atrial muscle where it has been shown that anandamide. 
methanandamide and HU-210 all cause negative isotropy (Bonz ei a l, 2003). The 
anandamide response- was shows to be due to CBi receptor activation because AM251, 
a CBi receptor selective antagonist, inhibited the negative inotropic response (Bonz ei 
a l, 2003).
The rate of spontaneous contraction in isolated right atria is derived from the activity of 
the sino-atrial node which is the pacemaker of the heart. This spontaneous heart rate is 
governed by the rate of depolarisation of the pacemaker cells (Satoh, 2003). 
Anandamide has been reported to have no effect on neuronaliv enhanced spontaneous 
rate (Lay ei a l, 2000). However, in that study, the effect of eannabinoids on 
spontaneous rate was not determined.
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In vivo, eannabinoids induce a triphasic hypotensive profile (Lake et al., 1997a; Varga 
et al., 1995). Initially there is a brief decrease in heart rate and blood pressure followed 
by a short-term vasopressor response followed by a prolonged decrease in heart rate. 
The principle fall in heart rate is related to the activation of TRPV1 which are primarily 
located on sensory neurones (Malinowska et al., 2001), and where anandamide is a full 
agonist (Smart et al., 2000). The later hypotensive response is sensitive to SR141716A 
and therefore has been ascribed to activation of CBi receptors (Malinowska et al., 
2001).
It is unclear whether the cannabinoid induced effects seen on heart rate are due to the 
influence of either the central or peripheral nervous system. By using rat spontaneously 
beating isolated right atria, the direct effects of eannabinoids on sino-atrial function can 
be studied without the involvement of potentially confounding responses mediated at 
the level of the central and peripheral nervous system. In addition, the potential role of 
interaction with /5-adrenoceptors was investigated by studying responses to 
eannabinoids in rat spontaneously beating isolated right atria treated with isoprenaline.
Isoprenaline stimulates /3-adrenoceptors causing the activation of adenylate cyclase 
leading to increased intracellular levels of the secondary messenger, cyclic AMP, which 
mediates an increase in heart rate (Whalen & Lewis, 1999). Cannabinoid-induced 
inhibition of adenylyl cyclase is the best characterised of the signal transduction 
pathways associated with cannabinoid receptor stimulation and anandamide is known to 
inhibit isoproterenol-induced accumulation of cyclic AMP (Childers & Deadwyler, 
1996).
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The aim of this series of experiments is to characterise the effects of eannabinoids on 
heart rate in the presence and absence of /3-adrenoceptor tone.
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3.2 Experimental Protocol
3.21 Agonist studies
All tissues were set up as described in 2.2.3. Agonists were introduced in a cumulative 
manner to naive right atria in a tissue bath in order to construct concentration-response 
curves. (-)-Isoproterenol hydrochloride (isoprenaline) at a concentration of 0.01/aM, 
where used, was added to the right atria prior to the addition of the agonist to cause an 
increase in heart rate. Bolus doses of agonist were added once the isoprenaline-induced 
increase in contractile rate had stabilised (5-10 minutes after addition). Enough time 
was allowed for each response to plateau before a subsequent agonist concentration was 
added. Only one cumulative concentration-response curve was constructed per 
individual preparation.
3.22 Antagonist studies
Antagonists or inhibitors (final concentration 1/xM), where used, were added 30 minutes 
before agonist addition (cannabinoid or isoprenaline) to allow equilibration. Only one 
concentration-response curve was constructed per individual preparation.
3.3 Drug preparation
The following drugs were used: Isoprenaline, capsazepine and indomethacin (all from 
Sigma, Gillingham, UK), anandamide and methanandamide (obtained as solutions of 
5mg/ml dissolved in Tocrisolve™ 100, a vehicle of 1:4 soya oil:water mixture 
emulsified with poloxamer FI88), AM281, AM404, JWH-133 (Tocris Cookson Ltd, 
Bristol, UK) and SR141716A and SRI44528 (gifts from Dr Barth of Sanofi-Aventis, 
Montpellier, France). Serial dilutions were made in Krebs bicarbonate solution in the
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case of isoprenaline, anandamide and methanandamide. Ascorbic acid (approximately 
ImM) was present in the stock solution of isoprenaline to prevent oxidation. AM281, 
AM404, SR141716A and SRI44528 were first dissolved in dimethyl sulfoxide (DMSO, 
Fisher Scientific, Leicestershire, UK) to give a stock concentration of 2mM followed by 
a 1:10 dilution in 50:50 DMSO to Krebs bicarbonate solution to give a final 
concentration of 1/xM in the organ bath. Indomethacin was dissolved in ethanol (Fisher 
Scientific, Leicestershire, UK) to give a final concentration of 1/xM in the organ bath.
3.4 Statistical analysis
Responses are expressed as percentage of the resting rate or as a percentage of the 
increase induced by isoprenaline and are reported as mean ± S.E.M. Statistically 
significant (P<0.05) differences between results were assessed with ANOVA supported 
by Dunnett's multiple comparison test against a single control.
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3.5 Results
3.51 Studies in naive isolated right atria 
3.51a Agonists Studies
Baseline rates did not significantly vary among any of the experimental groups (Table
3.1).
Tocrisolve™ 100 vehicle control administered at the equivalent amounts used to deliver 
eannabinoids had no significant effect on chronotropy in naive right atria (0.6 ± 0.7% of 
baseline rate at the highest concentration). Addition of anandamide to naive right atria 
resulted in a small but significant increase in chronotropy. The increases seen were 
concentration-dependent with the maximum mean increase in chronotropy (11 + 2% of 
baseline rate) induced by a concentration of 3xl0'5M. No significant alteration in 
baseline chronotropy was observed with methanandamide at any concentration when 
compared to the vehicle control (Figure 3.1)
3.51b Antagonist Studies
None of the antagonists significantly affected baseline rate (Table 3.1).
Tocrisolve™ 100 vehicle control had no significant effect on chronotropy in naive right 
atria in the presence of either DMSO (vehicle for SR141716A, SR144528, AM281, 
AM404 and capsazepine) or ethanol (vehicle for indomethacin, Figures 3.2 and 3.4 
respectively).
Anandamide in the presence of either DMSO or ethanol significantly increased 
chronotropy by 7 ± 2% and 13 ± 2% of baseline rate respectively (Figures 3.2 and 3.4 
respectively).
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The presence of SR141716A (1/xM), SR144528 (1/zM), AM281 (1/aM) or capsazepine 
(1/iM), had no significant effect on the anandamide-induced positive chronotropy 
(Figure 3.3). However the presence of AM404 significantly inhibited anandamide- 
induced positive chronotropy (Figure 3.3). Anandamide-induced positive chronotropic 
responses were also significantly inhibited by the presence of IfiM indomethacin 
(Figure 3.4).
3.52 Studies using isoprenaline-treated isolated right atria 
3.52a Agonist Studies
Addition of 0.0 lpM isoprenaline caused a significant increase in heart rate (150 ± 18% 
BPM of baseline levels, Table 3.2). Tocrisolve™ 100 vehicle control had no significant 
effect on the chronotropy induced by isoprenaline (Figure 3.5).
In isoprenaline-treated right atria, anandamide caused a significant negative chronotropy 
(Figure 3.5). The highest concentration used (3xlO'5M) caused an 80% decrease of the 
isoprenaline-stimulated chronotropy. Methanandamide at the same concentration (3x10' 
5M) also significantly decreased rate of atrial contraction by 46% of the isoprenaline- 
induced rate (Figure 3.5).
Addition of ACPA (selective CBi agonist) had no significant effect on chronotropy 
(Figure 3.5). However, the addition of JWH-133 (selective CB2 agonist) significantly 
reduced chronotropy by 51% of the isoprenaline-induced rate (Figure 3.5) at the highest 
concentration used (3xl0'5M).
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3.52b Antagonist Studies
None of the antagonists had a significant effect on baseline chronotropy (Table 3.3). 
Tocrisolve™ 100 vehicle control had no significant effect on chronotropy in right atria 
pre-treated with isoprenaline in the presence of DMSO (vehicle for SR141716A, 
SR144528 and AM281; Figure 3.6).
In isoprenaline-treated right atria, in the presence of DMSO anandamide caused a 
significant negative chronotropy (Figure 3.6). The highest concentration used (3x10' 
5M) caused a 38% decrease of the isoprenaline-stimulated heart rate.
The negative chronotropic response to anandamide in isoprenaline-treated right atria 
was not significantly affected by the presence of either SR141716A (lpM), AM281 (1 
pM) or AM404 (lpM). However the presence of lpM SR144528 significantly 
potentiated the negative chronotropic effect of anandamide, with the isoprenaline- 
induced rate being reduced by 90% of the isoprenaline-stimulated rate of atrial 
contraction. This was also the case for capsazepine where isoprenaline-induced rate 
was reduced to that of pre-isoprenaline-stimulated rates of atrial contraction (Figure 3.7).
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Table 3.1 Baseline contractile rate for naive right atria treated with Tocrisolve™ 100,
cannabinoid agonists, antagonists and the antagonist vehicle. Data expressed as mean ± S.E.M. $ 
signifies significant difference vs. baseline determined by Students unpaired t-test.
n Baseline
rate
(BPM)
Baseline 
following 
addition of 
antagonist 
(BPM)
Mean
maximal
response
(BPM)
Tocrisolve1M 100 6 287 ±7 288 ±8
Anandamide 11 290 ±6 321 ±7*
Methanandamide 4 301 ±5 308 ±9
DMSO + Vehicle 4 310± 12 307 ±7 303 ±8
DMSO + Anandamide 5 311 ±19 314 ± 16 334 ± 11
SR141716A + 
Anandamide
4 289 ±7 294 ±4 327 ± 14
AM281 + Anandamide 3 291 ±11 300 ±5 312 ± 13
SRI44528 + Anandamide 6 272 ± 10 273 ±8 302 ± 19
AM404 + Anandamide 7 308 ± 10 308 ±6 319± 8
Capsazepine + 
Anandamide
3 279 ± 16 287 ± 13 307 ±23
Ethanol+ 
Tocrisolve™ 100
4 310 ± 8 322 ± 13 317 ± 14
Ethanol + Anandamide 4 292 ± 27 297 ± 19 335 ±21
Indomethacin + 
Anandamide
7 313 ± 6 307 ±5 323 ± 12
BPM = beats per minute.
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Table 3.2 Baseline contractile rate for right atria treated with 0.01 (iM isoprenaline followed by
treatment with Tocrisolve™ 100 or various cannabinoid receptor agonists. Data expressed as mean ± 
S.E.M. * signifies significant difference vs. baseline and $ signifies significant difference vs. 
isoprenaline-induced rate determined by Students unpaired t-test.
n Baseline
rate
(BPM)
Isoprenaline- 
induced rate 
(BPM)
Mean
maximal
response
(BPM)
Isoprenaline + 
Tocrisolve™ 100
4 299 ± 12 446 ± 9 * 446 ±9
Isoprenaline + 
Anandamide
7 285 ± 12 426 ± 19 * 313 ± 15 s
Isoprenaline + 
Methanandamide
5 285 ±7 453 ±9* 375 ±25*
Isoprenaline + ACPA 3 296 ± 17 461 ±9* 425 ± 10 *
Isoprenaline + JWH-133 4 290 ± 10 457 ± 19 * 268 ±24*
BPM = beats per minute.
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Table 3.3 Baseline contractile rate for right atria treated with 0.01 pM isoprenaline followed by
treatment with agonist vehicle (Tocrisolve™ 100), antagonist vehicle (DMSO or Tocrisolve™ 100) or 
various combinations o f cannabinoid receptor agonists and antagonists. Data expressed as mean ± 
S.E.M. * signifies significant difference vs. baseline and $ signifies significant difference vs. 
isoprenaline-induced rate determined by Students unpaired t-test.
n Baseline
rate
(BPM)
Baseline 
following 
addition of 
antagonist 
(BPM)
Isoprenaline
(BPM)
Mean
maximal
response
(BPM)
DMSO + 
Isoprenaline + 
Tocrisolve™ 100
8 305 ±5 304 ±7 454 ± 4 * 451 ±7
DMSO + 
Isoprenaline + 
Anandamide
4 289 ±15 292 ± 10 434 ±17* 383 ±34
SR141716A + 
Isoprenaline + 
Anandamide
5 288 ± 12 286 ± 12 468 ± 5 * 343 ±35*
AM281 + 
Isoprenaline + 
Anandamide
5 299 ±8 306 ± 13 449 ± 13 * 416 ±14
SRI44528 + 
Isoprenaline + 
Anandamide
5 296 ±12 313 ±19 460 ± 9 * 336 ± 9 $
AM404 + 
Isoprenaline + 
Anandamide
5 284 ±5 302 ±9 448 ± 13 * 384 ±25
Capsazepine + 
Isoprenaline + 
Anandamide
3 298 ± 10 292 ± 17 463 ± 8 * 282 ± 17*
BPM = beats per minute.
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Figure 3.1 Concentration response curves for the effect o f anandamide (n = 11) and 
methanandamide (n = 4) on right atrial spontaneous rate. Effects of Tocrisolve™ 100 (vehicle for 
anandamide, n = 6) are shown for comparison. Error bars represent SEM. * P^O. 05 vs. vehicle control 
as determined by ANOVA supported by Dunnett’s post-hoc test.
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3.6 Discussion
The main findings of this study were that anandamide elicited either positive or negative 
chronotropic responses depending upon the state of the atria. In naive atria, anandamide 
causes a small, but significant positive chronotropy whilst in atria pre-treated with 
isoprenaline, negative chronotropic responses were observed. These findings 
demonstrate that responses to eannabinoids depend upon the presence or absence of /?- 
adrenoceptors tone and may go someway to explaining the lack of concordance when 
the effects of eannabinoids on heart rate are studied in vivo.
The data presented shows that anandamide caused a significant increase in chronotropy 
of isolated spontaneously beating right atria. This result demonstrates that in addition to 
previously reported activities on the central and peripheral nervous system (see reviews 
Felder & Glass, 1998; Howlett et al., 2002) anandamide can alter heart rate at the level 
of the sino-atrial node rather than altering central or peripheral nervous output. 
However, the biological significance of this response is questionable as the increase in 
heart rate is relatively small (11 ± 2% of baseline rate).
The positive chronotropic response to anandamide was not blocked by either of the 
classic cannabinoid receptor antagonists SR141716A (CBi receptor antagonist), or 
SRI44528 (CB2 receptor antagonist). However, AM404 the anandamide transporter 
inhibitor (Beltramo et al., 1997; Khanolkar & Makriyannis, 1999), reduced the positive 
chronotropy caused by anandamide providing evidence that the site of action for 
anandamide is intracellular. It was also found that anandamide-induced positive 
chronotropy was inhibited by indomethacin (a cyclooxygenase inhibitor) indicating that
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anandamides mechanism of action involved the formation of products of the 
cyclooxygenase pathway such as prostaglandins or prostacyclins (Belton & Fitzgerald, 
2003). Metabolism of anandamide by COX-2 (an inducible form of cyclooxygenase) 
has been shown to produce a novel class of prostaglandin (Yu et al., 1997), however, 
the biological significance of these pathways has yet to be discovered. There are a 
number of theories presently held about their significance. One suggests that 
oxygenation of anandamide may be an inactivation pathway. Another is that it is an 
activation pathway in which the metabolic stability of the products are increased above 
that of the parent endocannabinoids as the products of cyclooxygenase metabolism are 
less labile than the parent, therefore cyclooxygenase metabolism acts to increase the 
duration of the response. A third theory is that the oxygenated products of COX-2 
metabolism of eannabinoids are unique signal transduction mediators. Finally that 
oxidised endocannabinoids may serve as pro-drugs as the prostanoids produced are 
more metabolically stable than free-acid prostaglandins therefore having a longer half 
life to act as systemic mediators or pro-drugs (Kozak et a l, 2004; Patrignani et al., 
2005).
Methanandamide, which in previous studies was shown to have similar effects to 
anandamide in the heart, i.e. the triphasic effect (Malinowska et al., 2001), did not elicit 
the positive chronotropic effect seen with anandamide. This supports the finding that 
anandamide mediates positive chronotropy by uptake and release of products of 
cyclooxygenase as methanandamide is a non-hydrolysable analogue of anandamide 
(Abadji et al., 1994) and therefore insensitive to metabolism by cyclooxygenase.
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Paradoxically, anandamide reduced the rate of atrial contraction once chronotropy had 
been increased with isoprenaline. This negative chronotropic response, revealed by 
isoprenaline treatment, was mimicked by methanandamide and therefore independent of 
cyclooxygenase metabolism unlike the previously observed positive chronotropic 
response. Thus, eannabinoids appear to mediate opposing actions on contractile rate 
mediated by the sino-atrial node depending upon /3-adrenoceptor tone.
As the negative chronotropy induced by anandamide in the presence of isoprenaline was 
not due to release of cyclooxygenase products, the possibility that the response was 
mediated by activation of one of the classical cannabinoid receptors was investigated 
using agonists and antagonists selective for either CBi or CB2 receptors. ACPA the 
selective CBi agonist (Hillard et al., 1999) had no effect on isoprenaline-stimulated 
atrial contraction rate. However, treatment with JWH-133 a CB2 selective agonist 
(Huffman et al., 1999) resulted in a negative chronotropic response similar in 
magnitude to that caused by anandamide or methanandamide. This suggests that the 
negative chronotropy seen with anandamide and methanandamide in the presence of 
isoprenaline is mediated via CB2 receptors.
If the anandamide-mediated negative chronotropy was the result of CB2 receptor 
activation it would be expected that SRI44528 (selective CB2 antagonist) would have 
blocked this response. However, this was not the case as the presence of SRI44528 
significantly potentiated the negative chronotropic effect. This finding would suggest 
that CB2 receptor activation causes an increase in heart rate and by blocking this 
response using SRI44528 reveals a functional antagonism resulting in the potentiation
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of the negative chronotropy. This data clearly does not fit with that obtained using 
JWH-133 where negative chronotropy was induced. A possible explanation for this 
could be that SRI44528 was not used at a sufficiently high concentration to block CB2 
receptors. However, we used a concentration of 1 pM which has been previously shown 
to effectively antagonise responses mediated by CB2 receptors (Rinaldi-Carmona et al., 
1998).
AM404 did not significantly affect the negative chronotropic effect of anandamide. 
This result suggests that the site of action for cannabinoid-mediated negative 
chronotropy in the presence of isoprenaline is not intracellular, which confirms the 
results seen in the presence of methanandamide.
Another receptor which could be involved in the negative chronotropic effect of 
anandamide is TRPV1. However, the TRPV1 antagonist capsazepine did not block the 
negative chronotropy seen, in fact; the presence of this antagonist potentiated the effect. 
This is similar to that seen in the presence of SR144528 and again could be due to 
activation of TRPV1 causing an increase in heart rate and thus by blocking this 
response using capsazepine we revealed a functional antagonism resulting in the 
potentiation of the negative chronotropy.
It would appear that at least two mechanisms are involved in the regulation of heart rate. 
One, which increases (positive chronotropy) and another, which decreases (negative 
chronotropy) heart rate. Physiologically, the latter effect would be observed upon 
sympathetic stimulation. Isoprenaline activates adenylate cyclase leading to increased
71
intracellular levels of the secondary messenger, cyclic AMP, that mediates an increase 
in heart rate (Whalen & Lewis, 1999). Anandamide is known to inhibit isoproterenol- 
induced accumulation of cyclic AMP (Childers & Deadwyler, 1996). This has 
prompted the notion that there is a novel G-protein-coupled receptor for cannabinoids 
distinct from the neuronal CBi receptor because inhibition of the isoproterenol-induced 
accumulation of cyclic AMP was insensitive to CBi antagonists (Sagan et al, 1999). 
Investigation into this novel receptor has focused on neurons and astrocytes, where the 
same agonist profile has been demonstrated but it was only in the astrocytes where 
SR141716A did not block the inhibition of the isoproterenol-induced accumulation of 
cyclic AMP by anandamide. This novel receptor has been shown to be more abundant 
in astrocytes than in neurons as specific binding sites for [3H]-SR141716A and staining 
with a polyclonal CBi receptor antibody was only observed in neurons not astrocytes 
(Sagan et al, 1999). As cannabinoids opposed the increase in rate of contraction 
induced by isoprenaline at an intracellular site, it is possible that cannabinoids might 
inhibit the activity of adenylyl cyclase or some other downstream component of the |8- 
adrenoceptor transduction pathway. It could be speculated that addition of anandamide 
to heart tissues would inhibit cyclic AMP and the rate of contraction would diminish as 
was shown by a decrease in heart rate.
Both CBi and CB2 receptor protein has been found in rat hearts using western blot 
analysis with rabbit polyclonal antibodies (Bouchard et al, 2003), however, prior to this 
it had been reported that there was a lack of CB2 mRNA in the rat heart (Brown et al, 
2002). The data presented shows that functionally, neither CBi nor CB2 are involved in 
the positive chronotropic effect of anandamide on nai've right atria because neither CBi
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receptor antagonists (SR141716A and AM281) nor a CB2 receptor antagonist 
(SRI44528) significantly inhibited anandamide-induced positive chronotropy. 
However, the selective CB2 agonist, JWH-133 (Pertwee, 1999) caused the negative 
chronotropic effect seen with anandamide in right atria pre-treated with isoprenaline 
again suggesting two different pathways in the involvement of cannabinoids on the 
heart.
This investigation demonstrates that cannabinoids elicit a number of responses in the 
cardiovascular system which are independent of the influences of the central and 
peripheral nervous system and that these are due to separate mechanisms of action. 
This study also shows that the response to cannabinoids depends upon the state of the 
tissue. For example in this study anandamide has been shown to fine tune heart rate by 
increasing the rate all be it by a small amount in the absence of sympathetic tone and 
also reducing the rate in its presence.
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Investigation into the cardioprotective role of 
endocannabinoids in a model of global ischaemia
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4.1 Introduction
Two studies indirectly implicate endocannabinoids in the protection against myocardial 
ischaemia-reperfusion injury. One reports the involvement of cannabinoids in 
protection afforded by lipopolysaccharide treatment (Lagneux & Lamontagne, 2001) 
and the other implicates endocannabinoids in the limitation of infarction induced by 
heat stress preconditioning (Joyeux et al., 2002). In both studies SR144528 the CB2 
receptor antagonist inhibited the protective effects of the treatments indicating that 
activation of the CB2 receptor is involved.
CB2 receptor involvement in cardioprotection has further been reported upon in a study 
by Lepicier et al. (2003). In that study palmitoylethanolamide and 2- 
arachidonoylglycerol but not anandamide were shown to improve recovery and reduce 
infarct size in a low-flow model of global ischaemia. A selective CBi agonist, ACEA 
and a selective CB2 agonist, JWH-015 also limited infarction. The results from this 
study are confusing because palmitoylethanolamide is a weak ligand at both the 
cannabinoid receptors (Lambert et al., 1999) and was shown to be devoid of any 
activity when administered to isolated rat hearts (Ford et al., 2002).
The pharmacology of 2-arachidonoylglycerol and anandamide are very similar as both 
bind and stimulate the CBi and CB2 receptors (Steffens et al., 2005; Sugiura et al., 
2000). Therefore the difference seen between these endocannabinoids in the Lepicier 
study are unlikely to be due to contrasting affinities or efficacies at the cannabinoid 
receptors particularly as protection could be induced by the selective agonists. It has 
been suggested that anandamide may not have been effective because it was rapidly
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degraded, however, this is unlikely to be the case as both anandamide and 2- 
arachidonoylglycerol are sensitive to uptake and metabolism (Goparaju et al., 1998; 
Laine et a l, 2002) therefore differences are unlikely to be due to different rates of 
degradation.
Given the confusion about the effectiveness of endocannabinoids in mediating 
cardioprotection we decided to assess whether anandamide could limit infarct size 
induced by ischaemia-reperfusion injury measured directly using tetrazolium chloride in 
rat isolated hearts and identify the pharmacological mechanism.
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4.2 Experimental protocols
A constant pressure Langendorff buffered-perfused heart preparation was used with rat 
hearts undergoing a period of global ischaemia. A detailed description of this 
preparation can be found in section 2.3. In brief, following attachment of the aorta to 
the cannula and immersion of the heart into the organ bath, hearts were aerobically 
perfused for the first 15 minutes (baseline values taken at 10 minutes and pre-ischaemic 
values at 15 minutes). 5 minutes prior to the ischaemia hearts were infused with either 
vehicle or agonist at 10% of the flow rate. Hearts then underwent a 30 minute period of 
no-flow global ischaemia induced by clamping the perfusion line to the heart.
Vehicle or agonists were infused (at 10% of the flow rate) at the same time as 
reperfusion commenced and continued throughout the following 2 hours of reperfusion. 
Figure 4.1 shows the experimental protocol used for these experiments.
Baseline Global ischaemia Reperfusion
Drug infusion Drug infusion
0 15 45 165
Figure 4.1 Diagrammatic representation o f the global ischaemia protocol. Hearts were
aerobically perfused for the first 15 minutes (black). Baseline values were taken at 10 minutes and pre- 
ischaemic values were taken just before ischaemia was induced at 14 minutes. Reperfusion commenced 
after 30 minutes o f global, no-flow ischaemia (red). Hearts were reperfused for 2 hours (blue) and then 
frozen. Reperfusion values were reported at the end o f the protocol, before hearts were removed and 
frozen ready for tetrazolium chloride staining. The arrows indicate the infusion o f agonists or their 
vehicle. Antagonists or their vehicle (DMSO) where used, were present throughout the protocol.
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At the end of reperfusion the intraventricular balloon was deflated and removed. The 
hearts were then cut from the cannula, frozen and sliced into 5 or 6 transverse sections 
approximately 4mm thick with a single edged razor. The slices were then placed in a 
beaker containing a 1% solution of triphenyltetrazolium chloride for 5-10 minutes until 
a brick red colour had developed. Stained hearts were then stored in a 10% formalin 
solution (formaldehyde solution, phosphate buffered, pH 7.3) for 24 hours. The right 
ventricle and connective tissues were then removed. The stained slices were flattened 
between two glass plates separated by 2.5mm. Areas with an absence of red stain 
(infarcted area) were traced onto an acetate sheet by an investigator blinded to the 
experimental protocol. Acetate tracings were scanned into a PC running SigmaScan Pro 
5 (Hounslow, UK) and the areas (in pixels) of infarction or viable tissue calculated. 
Infarct size is reported as the area unstained by triphenyltetrazolium chloride expressed 
as a percentage of the area at risk. Figure 4.2 shows a typically stained heart.
Connective tissue
Infarction
Figure 4.2 Picture showing a typical example o f the sections o f a stained heart
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4.21 Agonist Studies
• T UHearts were randomly assigned to receive the cannabinoid vehicle, Tocnsolve 100 (a 
vehicle of 1:4 soya oil:water mixture emulsified with poloxamer FI88, Tocris Cookson 
Ltd, Bristol, UK), or one of the following cannabinoid agonists (lpM): anandamide, 
methanandamide, HU-210, arachidonlycyclopropylamide (ACPA), JWH-133 or a 
combination of ACPA and JWH-133. Cannabinoid agonists or Tocrisolve™ 100 
vehicle were infused at a flow rate controlled to be 10% of coronary flow.
4.22 Antagonist studies
Where used, antagonists were present in the perfusate throughout the protocol. 
Antagonists were prepared in dimethyl sulfoxide (DMSO) as a ImM stock solution 
before being added to the perfusate (final concentration lpM).
Hearts were randomised to one of three groups. The first consisted of the antagonist 
vehicle DMSO (0.01% vol.vol-1). The second group was treated with SR141716A and 
the third group with SR144528.
4.3 Drug preparations
The cannabinoid agonists, anandamide, methanandamide, ACPA, JWH-133 and HU- 
210 (Tocris Cookson Ltd, Bristol, UK) obtained as solutions of 5mg/ml dissolved in 
Tocrisolve™ 100 were diluted in Krebs bicarbonate solution to a concentration of 10" 
5M so  that when infused at a rate controlled to be 10% of coronary flow a final 
concentration of lpM was obtained. The cannabinoid agonist vehicle Tocrisolve™ 100 
was diluted in Krebs bicarbonate to give a concentration of 0.07% solution that when 
infused at 10% of coronary flow a final concentration of 0.007% was obtained.
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SR141716A and SRI44528 (gifts from Dr Barth of Sanofi-Aventis, Montpellier, 
France) were prepared in DMSO (Fisher Scientific, Leicestershire, UK) as ImM stock 
solutions and added to the perfusate (final concentration was lpM).
4.4 Statistical analysis
All data are expressed as the mean ± SEM of n experiments. Unpaired data were 
compared using an unpaired Student’s t-test. Multiple comparisons against a single 
control were made using analysis of variance (ANOVA) followed by Dunnet’s post hoc 
test (GraphPad InStat 3.0, California, USA). ANOVA with repeated measures was used 
to compare time course data (SPSS Inc., Chicago, USA). Statistical significance was 
taken at P <0.05.
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4.5 Results
4.51 Agonists Studies
Diastolic pressure, left ventricular developed pressure and coronary flow did not 
significantly vary among any of the experimental groups before ischaemia (Table 4.1).
In vehicle treated (Tocrisolve™ 100) control hearts, diastolic pressure, markedly 
elevated at the beginning of reperfusion, fell steadily throughout reperfusion and 
remained significantly elevated compared to pre-ischaemic values by the end of 
reperfusion (Figure 4.3). Left ventricular developed pressure recovered incompletely 
during reperfusion recovering to a maximum of 40 ± 6% of pre-ischaemia values after 
50 minutes of reperfusion. After 50 minutes of reperfusion there was a steady decline 
in left ventricular developed pressure until the end of reperfusion such that by the end of 
reperfusion, the values were 29 ± 6% of pre-ischaemic values (Figure 4.3 and Table
4.1). Recovery of coronary flow during reperfusion was also incomplete reaching a 
maximum (37 ± 7% or pre-ischaemic values) after 20 minutes of reperfusion then 
declining to 24 ± 6% of pre-ischaemic values by the end of reperfusion (Figure 4.3 and 
Table 4.1). Infarct size, measured at the end of reperfusion was 26 ± 3% of the left 
ventricle (Figure 4.4 and Table 4.1).
None of the cannabinoid agonists used in the study had a significant effect on the 
recoveries of diastolic pressure, left ventricular developed pressure or coronary flow 
compared to control hearts (Figure 4.3 and Table 4.1). However, infarct size was 
significantly reduced by the presence of anandamide (10 ± 1% of the left ventricle) and 
methanandamide (12 ± 4% of the left ventricle) compared to hearts which received
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vehicle (Figure 4.4 and Table 4.1). Infarct size in hearts treated with ACPA (26 ± 5% 
of the left ventricle) or JWH-133 (20 ± 2% of the left ventricle) individually or in 
combination (27 ± 4% of the left ventricle) were not significantly different from those 
obtained in vehicle control hearts (Figure 4.4 and Table 4.1).
4.52 Antagonist studies
Diastolic pressure, left ventricular developed pressure and coronary flow did not 
significantly vary among any of the experimental groups before ischaemia (Table 4.2).
In vehicle (Tocrisolve™ 100) control hearts with 0.01% vol.vol'1 DMSO present, 
diastolic pressure was markedly elevated at the beginning, falling steadily throughout 
but remaining elevated by the end of reperfusion (Figure 4.5). Recovery of left 
ventricular developed pressure was incomplete reaching a maximum of 33 ± 8% of pre- 
ischaemic values after 40 minutes of reperfusion then falling to 18 ± 4% of pre- 
ischaemic values by the end of reperfusion (Figure 4.5). Coronary flow was impaired 
during reperfusion recovering to a maximum of 33 ± 7% of pre-ischaemic values after 
20 minutes of reperfusion then falling to 17 ± 1% of pre-ischaemic values by the end of 
reperfusion (Table 4.2). Measured at the end of reperfusion, 28 ± 3% of the left 
ventricle was infarcted (Figure 4.8 and Table 4.2).
The recoveries of diastolic pressure, left ventricular developed pressure and coronary 
flow were not significantly different from vehicle (Tocrisolve™ 100) control hearts 
treated with 0.01% vol.vol'1 DMSO in hearts where SR141716A (lpM, Figure 4.6) or 
SR144528 (lpM, Figure 4.7) were present. Infarcts obtained in hearts where
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SR141716A or SR144528 were present (Figure 4.8 and Table 4.2) were similar to those 
in their absence.
Infusion of anandamide in the presence of 0.01% vol.vol’1 DMSO had no significant 
effect on the recovery of diastolic pressure, left ventricular developed pressure or 
coronary flow during reperfusion compared to vehicle control hearts (Figure 4.6 and 
Table 4.2). However infarct size, measured at the end of reperfusion, was significantly 
reduced to 12 ± 2% of the left ventricle (Figure 4.8 and Table 4.2).
The combination of SR141716A or SR144528 with anandamide infusion had no 
significant effect on recoveries of diastolic pressure, left ventricular developed pressure 
or coronary flow during reperfusion compared to SR141716A or SR144528 with the 
vehicle control (Tocrisolve™ 100; Figures 4.6 and 4.7 and Table 4.2). However, the 
infarct size reduction observed when anandamide was infused alone was lost in the 
presence of either SR141716A or SR144528 (Figure 4.8 and Table 4.2).
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Table 4.1 Cardiac Junction and infarct size in hearts treated with cannabinoid agonists.
Perfiision
Time
(min)
n Diastolic
pressure
(mmHg)
LVDP
(mmHg)
CF
(ml.min'1)
Infarct 
size 
(% of 
LV)
10 9±1 106±8 15±1
Tocrisolve™ 15 13 8±1 100±6 M il 26i3
100 135 41±9 19±3 2±1
Anandamide 10 6±1 104±10 16±1
(lpM) 15 7 5±2 l l l i l l 18il 10il
135 41il3 27±3 5il
mAEA 10 9±2 95±20 12±1
(lpM) 15 6 10±1 92±16 M il 12i4
135 27±5 21±5 3 il
ACPA 10 7±2 91±13 12il
(lpM) 15 6 11±2 87±10 13il 26i5
135 34±12 22±2 4 il
JWH-133 10 8±1 83±10 13il
(ljxM) 15 8 11±1 89±16 13il 20i2
135 33±5 20±4 2 il
ACPA + 10 13±1 93±8 12il
JWH-133 15 9 12±2 94±6 13il 27i4
(lpM each) 135 53±6 16±3 4 il
LVDP = left ventricular developed pressure, CF = coronary flow, LV = left ventricle and mAEA = 
methanandamide. Absolute values are given as mean + s.e.m. with n the number o f hearts in the group.
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Table 4.2 Cardiac function and infarct size in hearts treated with cannabinoid agonists and in the
presence of the cannabinoid antagonists.
Perfusion
Time
(min)
n Diastolic
pressure
(mmHg)
LVDP
(mmHg)
CF
(ml.min'1)
Infarct 
size 
(% of 
LV)
10 10±1 101±10 13±2
Tocrisolve™ 15 1 9±2 96±9 13±1 28±3
100 135 41±11 18±5 2±1
Anandamide 10 7±1 100±11 15±1
(lpM) 15 1 7±2 103±11 17±1 12±3
135 51±9 22±3 4±1
SR141716A 10 16±2 88±6 12±2
(IpM) 15 6 16±2 82±5 12±2 18±2
135 56±6 15±3 2±1
SR141716A 10 12±1 81±3 13±1
+anandamide 15 6 12±1 81±5 13±1 20±4
(luM) 135 53±6 22±1 3±1
SR144528 10 9±2 113±9 15±1
(lpM) 15 6 12±1 108±8 14±1 23±3
135 58±9 14±3 5±2
SR144528 + 10 9±1 98±5 18±1
anandamide 15 8 8±1 100±5 18±1 22±2
(luM) 135 22±8 26±5 5±1
LVDP = left ventricular developed pressure, CF = coronary flow, LV = left ventricle and mAEA = 
methanandamide. Absolute values are given as mean ± s.e.m. with n the number o f hearts in the group.
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Figure 4.3 Left ventricular developed pressure (L VDP), coronary flow (CF) and diastolic pressure
for hearts treated with Tocrisolve™ 100 (control, D, n = 13) or lpM anandamide (AEA, 0, n = 7), lpM  
methanandamide (mAEA, T, n = 6), 1/jM  ACPA (M, n = 6), IpM JWH-133 (O, n = 8), and a 
combination o f IpM ACPA and lpM JWH-133 ( 0, n = 8). The same control group appears in all 
panels. Left ventricular developed pressure, diastolic pressure and coronary flow did not significantly 
vary among any o f the experimental groups (ANOVA with repeated measures o f analysis).
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Figure 4.4 Infarct sizes for individual hearts treated with Tocrisolve™ 100 (n = 13) or lpM 
anandamide (n = 7), lfjM methanandamide (n = 6), 1 pM ACPA (n = 6), 1/jM  JWH-133 (n = 8), and a 
combination of 1/jM  ACPA and lpM JWH-133 (n =9). * = P<0.05 vs. control (ANOVA supported by 
Dunnett’s post hoc test).
87
20-i
Time (min)
B. 10 -LLO
50 100
Time (min)
100-i
£ o>°-i
.9 . |  50- 
o  3 ,
o 50 100 150
Time (min)
□ Tocrisolve™ 100 + DMSO ■  Anandamide + DMSO
Figure 4.5 Left ventricular developed pressure (LVDP), coronary flow (CF) and diastolic pressure 
for hearts treated with Tocrisolve™ 100 (n = 8) or 1/jM  anandamide (n = 7) in the presence o f 0.01%  
DMSO. There were no significant differences in recoveries o f coronary flow, left ventricular developed 
pressure or diastolic pressure among any of the factors (ANOVA with repeated measures o f analysis).
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Figure 4.6 Left ventricular developed pressure (LVDP), coronary flow (CF) and diastolic pressure
for hearts treated with Tocrisolve™ 100 (n = 6) or lpM anandamide (n = 6) in the presence o f ljuM 
SR141716A. There were no significant differences in recoveries of coronary flow, left ventricular 
developed pressure or diastolic pressure among any of the factors (ANOVA with repeated measures of 
analysis).
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Figure 4.7 Left ventricular developed pressure (L VDP), coronary flow (CF) and diastolic pressure
for hearts treated with Tocrisolve™ 100 (n = 6) or lpM anandamide (n = 8) in the presence of lpM 
SR144528. There were no significant differences in recoveries o f coronary flow, left ventricular 
developed pressure or diastolic pressure among any of the factors (ANOVA with repeated measures of 
analysis).
90
©o
© cN © '© ^ 
& O ©
©c -c
& '  / "  ^  JO
>
"ft>I PX '
#K
V
Figure 4.8 Infarct sizes for individual hearts treated with Tocrisolve™ 100 in the absence (n = 7)
and presence of lpM SR141716A (n = 6) or lpM SRI44528 (n = 6) or lpM anandamide in the absence 
(n = 7) or presence of SR141716A (n = 6) or SRI44528 (n = 8) are shown. * = P<0.05 vs. control 
(ANOVA supported by Dunnett’spost hoc test).
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4.6 Discussion
This is the first study to demonstrate that anandamide reduces infarction induced by 
ischaemia-reperfusion when administered prior to ischaemia in rat isolated 
Langendorff-buffered perfused hearts. This infarct limiting action was not mimicked by 
the selective cannabinoid agonists ACPA (CBi) and JWH-133 (CB2) either on their own 
or in combination. Furthermore anandamide-induced infarct size limitation was 
blocked in the presence of both SR141716A and SRI44528, antagonists regarded as 
selective for CBi and CB2 receptors, respectively.
The findings that anandamide-induced infarct limitation was blocked by the presence of 
SR141716A or SRI44528 raised the possibility that stimulation of both CBi and CB2 
receptors or activation of one or more novel cannabinoid sites of action by anandamide 
was required to limit cardiac infarction associated with ischaemia-reperfusion. 
However, since neither ACPA nor JWH-133 alone or in combination reduced infarction 
activation of either CBi or CB2 alone, or together, does not appear to account for 
cardioprotection induced by anandamide. Therefore it could be inferred that the 
anandamide response is a result of activation of one or more unidentified receptors.
The first indications that endocannabinoids might play a role in reducing ischaemia- 
reperfusion injury came from evidence concerning lipopolysaccharide-induced 
(Lagneux & Lamontagne, 2001) and heat stress-induced (Joyeux et al., 2002) 
preconditioning. Both of these types of preconditioning were sensitive to SR144528 
(CB2 selective antagonist) but not to SR141716A (CBi selective antagonist), leading to 
the conclusion that the cardioprotective effect was as a result of CB2 receptor activation.
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A more recent study has examined the direct cardioprotective effects of cannabinoids 
(Lepicier et al., 2003). In that study a low flow (0.5-0.6ml/min) model of global 
ischaemia was used and the endocannabinoids palmitoylethanolamide and 2- 
arachidonoylglycerol were shown to reduce infarction, where infarction was measured 
directly by infarct size and indirectly by assessing the levels of creatine kinase and 
lactate dehydrogenase (biochemical markers of cellular damage). Anandamide (0.3 pM) 
a relatively non-selective endocannabinoid (Glass & Northup, 1999) was ineffective at 
reducing levels of creatine kinase and lactate dehydrogenase which leaked into the 
coronary effluent. In our study we have shown that anandamide (lpM) significantly 
reduced infarct size by more than 50% compared to the vehicle-treated hearts. This 
clearly contradicts the findings in the previous investigation. This contradiction could 
be the result of a number of methodological differences between the two studies. One 
major difference is the vehicles, which were used to deliver anandamide. Lepicier et al. 
(2003) used propylene glycol (1:9 vol.vol'1 with Krebs-Henseleit buffer) whereas 
Tocrisolve™ 100 was used here. Responses to anandamide in Tocrisolve™ 100 have 
previously been reported (Begg et al., 2002; Ford et al., 2002; Kwolek et al., 2005) 
whereas we are unaware of any reports where anandamide responses have been 
demonstrated with propylene glycol as the vehicle for anandamide. This is a major 
consideration given that responses to anandamide can be lost depending upon the 
solvent/vehicle used (Lopez-Miranda et al., 2004).
In their study, Lepicier et al. (2003) found that ACEA (selective CBi agonist) or JWH- 
015 (CB2 selective agonist), were able to reduce infarct size to a similar degree as 
palmitoylethanolamide and 2-arachidonoylglycerol. However, in the present study,
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neither ACPA, a selective CBi agonist (Hillard et al., 1999), nor JWH-133, a selective 
CB2 receptor agonist (Huffman et al., 1999), reduced infarction when used individually 
or in combination. At present, we have no explanation for the differences in response to 
CBi and CB2 receptor agonists between our study and that of Lepicier et al. (2003). 
Differences in the pharmacology of the agonists used in the two are not sufficient to 
explain the disparities, indeed the selective agonists in our study were used at higher 
concentrations than those used by Lepicier et al. (2003). However, the difference could 
be due to the choice of vehicle as Lepicier et al. (2003) used ethanol in contrast to 
Tocrisolve™ 100 used in this study. Therefore, it could be argued that ACPA and 
JWH-133 are biologically inactive when delivered in Tocrisolve™ 100, as these 
preparations have not been extensively tested.
Cannabinoids are known to mediate responses via a number of different mechanisms, 
one of which is uptake and metabolism to form products of the arachidonic acid cascade 
(Ellis et al, 1995; Kozak et al., 2002). As methanandamide, a non-hydrolysable 
analogue of anandamide (Abadji et al., 1994), also reduced infarct size, it is unlikely 
that the mechanism of cannabinoid-induced cardioprotection involves uptake, 
metabolism and release of arachidonic acid metabolites.
Both anandamide and methanandamide are known to activate TRPV1 (Malinowska et 
al., 2001; Smart et al., 2000). SR141716A has not been shown to block TRPV1 
mediated responses (del Carmen Garcia et al, 2003) therefore because SR141716A was 
effective in blocking the infarct limiting effect of anandamide, it is unlikely that this 
process is mediated via activation of TRPV1.
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Cannabinoid responses can also be mediated by two receptor subtypes that have been 
identified and cloned, namely CBi (Matsuda et al., 1990) and the CB2 receptor (Munro 
et al., 1993). Anandamide can bind and activate both of these receptors (Vogel et al., 
1993; Zoratti et al., 2003) although there are also examples where anandamide has not 
activated CB2 receptors (Bayewitch et al., 1995; Facci et al., 1995). Methanandamide, 
on the other hand, is a relatively selective agonist for the CBi receptor (Mechoulam et 
al., 1998). Therefore it would appear that the infarct limiting actions of anandamide 
and methanandamide are as a result of the activation of the CBi receptor. However, the 
selective CB2 antagonist, SR144528 as well as SR141716A (selective CBi antagonist) 
blocked the infarct-limiting response of anandamide. There are two explanations for 
this, firstly the infarct limiting action of anandamide requires both CBi and CB2 
receptors to be co-stimulated so that if one was blocked the cardioprotective response 
would be lost and secondly that the response to anandamide is mediated by a receptor 
distinct from either CBi or CB2 but which is sensitive to the two cannabinoid 
antagonists.
We found that individually neither the selective CBi agonist ACPA (Hillard et al., 
1999) nor the selective CB2 agonist JHW-133 (Pertwee, 1999) reduced infarct size. 
This would be expected if co-stimulation of the receptors was required. However, when 
the agonists were used in combination, the size of infarction should have been reduced 
but our data demonstrates that this is not the case suggesting that the anandamide- 
induced cardioprotection is not mediated by synergistic activation of CBi and CB2 
receptors, favouring the theory that the response is mediated at a site distinct from these 
receptor subtypes.
The presence of a cannabinoid receptor distinct from either the CBi or CB2 receptor 
located on endothelial cells has recently been proposed (Mo et al., 2004). Anandamide 
is thought to be able to activate this receptor therefore activation of the putative 
endothelial cannabinoid receptor (Jarai et al, 1999) may play a role in the mechanism 
of anandamide infarct size limitation. However, SRI44528 abolished the response to 
anandamide which indicates that the putative endothelial cannabinoid receptor is not 
involved as it is reportedly insensitive to this antagonist (Mo et al., 2004).
It has previously been reported that anandamide mediates cardiac responses such as 
negative inotropy and coronary vasodilation through interaction with a novel site 
distinct from any of the known cannabinoid pathways (Ford et al., 2002). The 
pharmacological profile of the anandamide infarct limiting effect seen in this study is 
the same as that previously reported (Ford et al., 2002). Therefore, it would appear that 
in addition to that study anandamide reduces infarct size by interaction with one or 
more novel mechanisms of cannabinoid signal transduction similar to those, which 
mediate negative inotropy and coronary vasodilation.
In summary, we have shown that anandamide and its stable analogue methanandamide 
limit infarct size associated with myocardial ischaemia-reperfusion without affecting 
contractile recovery. The pharmacological profile of this response is the same as that 
previously reported for anandamide-induced cardiac responses (Ford et al., 2002) and 
fails to match with any of the previously known mechanisms of cannabinoid action. We 
therefore conclude that anandamide reduces infarct size in rat isolated hearts by
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interaction with one or more novel sites of action that might involve a new cannabinoid 
receptor subtype.
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Chapter 5
Investigation into the role of endocannabinoids 
on ischaemia-reperfusion injury induced in a 
regional ischaemic model
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5.1 Introduction
In the previous chapter, hearts subjected to global no-flow ischaemia were used to test 
whether cannabinoids protect the myocardium from ischaemia-reperfusion injury. 
However, whole heart ischaemia is not a common clinical occurrence mainly being 
limited to cardiac transplantation. The most common clinical manifestation of cardiac 
ischaemia occurs during myocardial infarction where an occlusion, caused when a 
ruptured atherosclerotic plaque, blocks a coronary artery causing the area downstream 
from the plaque to become ischaemic. During a myocardial infarction the whole heart 
would not be affected, instead a smaller area would be subjected to ischaemia- 
reperfusion injury.
Another limitation of a global ischaemia model is that it cannot be guaranteed that drug 
treatment will reach all areas of a heart, which has been subjected to global ischaemia, 
whereas in a regionally ischaemic heart the area is smaller and therefore there is a 
greater likelihood that the drug will reach all the areas that have been damaged. In the 
global model the drug is applied before ischaemia and therefore it could also be argued 
that the results seen are due to preconditioning. Instead the drug could be introduced at 
reperfusion however, coronary flow is a limiting factor and therefore drug penetration 
may be compromised. For these reasons a regional model of cardiac ischaemia was 
chosen to better model the clinical situation.
The current clinical treatment for patients suffering occlusion is either thrombolytics or 
coronary artery angioplasty. Thrombolytics should be given as soon as possible 
(preferably in the first two hours after the onset of symptoms) so as to increase
99
myocardial salvage (Department of Health, 2000). It would be beneficial to introduce a 
drug at this stage which would not interfere with the restoration of flow but would help 
to limit the subsequent damage caused by the onset of reperfusion.
The regional ischaemia model does have its own drawbacks in that for a myocardial 
infarction to occur in a clinical situation the patient would have other 
pathophysiological features for example atherosclerosis, which are not present in this 
method as hearts have been harvested from rats without any apparent cardiovascular 
disease.
Regional ischaemia models are widely used to assess cardioprotection. This model has 
previously been used to investigate ischaemia-reperfusion with examples as diverse as 
insulin-mediated cardioprotection (Jonassen et al., 2001), to assess at what time point 
adenosine would need to be present at reperfusion for it to be cardioprotective (Xu et 
al., 2003) and to assess if preconditioning can limit infarct size in a mouse model 
(Miller & Van Winkle, 1999). At present there have been no investigations into the 
cardioprotective effects of cannabinoids using this model.
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5.2 Experimental protocol
A constant pressure Langendorff buffered-perfused heart preparation was used with 
hearts undergoing a period of regional ischaemia. A detailed description of the 
methodology can be found in section 2. 3. In brief, following the attachment of the 
aorta to the cannula and immersion of the heart into an organ bath, hearts were 
aerobically perfused for the first 15 minutes (baseline values taken at 10 minutes and 
pre-ischaemic values at 15 minutes) before undergoing a 40 minute period of ischaemia 
induced by tying a snare around the left anterior descending coronary artery (Figure 5.1 
shows the position of the left anterior descending coronary artery and where the snare 
was placed).
Right coronary
Snare
Left coronary r Surgical thread
Plastic tubing
Figure 5.1 Diagram o f the heart showing the position o f the snare. Regional ischaemia is induced 
by ligating the left anterior descending coronary artery. To prevent tearing o f the heart tissue and also to 
facilitate reperfusion, the occluding ligature is tied against a small length o f plastic tubing. Reperfusion 
is induced by releasing the snare.
Agonists were infused 35 minutes into ischaemia with the infusion continuing 
throughout the subsequent 1 hour of reperfusion. Reperfusion was defined as occurring
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once the snare around the left anterior descending coronary artery was released. Figure 
5.2 shows the experimental protocol used for these experiments.
Baseline Regional ischaemia Reperfiision
4" »
Agonist infusion
0 15 55 115
Time (min)
Figure 5.2 Diagrammatic representation o f the regional ischaemia protocol.
Hearts were aerobically perfused for the first 15 minutes (black). Baseline values were taken at 10 
minutes and pre-ischaemic values were taken just before ischaemia was induced. Reperfusion 
commenced after 40 minutes of ischaemia (red). Hearts were reperfused for 1 hour (blue) and then 
frozen. Reperfusion values are reported at the end o f the protocol, before hearts were removed and 
infused with Evans blue dye and subsequently frozen ready for TTC staining. The arrows indicate the 
presence o f vehicle (Tocrisolve™ 100)/agonist. Antagonists or their vehicle (DMSO), where used, were 
present throughout the protocol.
At the end of reperfusion the intraventricular balloon was deflated and removed. The 
snare was retied and hearts were infused with 0.25% Evan’s blue dye solution, frozen 
and sliced into 5 or 6 transverse sections approximately 4mm thick with a single edged 
razor. Areas of connective tissue were removed during this process. The slices were 
then placed in a beaker containing a 1% solution of triphenyltetrazolium chloride for 5- 
10 minutes until a brick red colour had developed. Stained hearts were stored in a 10% 
formalin solution (formaldehyde solution, phosphate buffered, pH 7.3) for 24 hours. 
The stained slices were flattened between two glass plates separated by 2.5mm. Areas 
stained blue by the Evan’s blue stain indicated the area which was not at risk of
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infarction, the presence of a red stain (triphenyltetrazolium chloride) indicated the 
viable cells within the area at risk of infarction and the absence of any staining indicated 
areas of infarction. These areas were traced onto an acetate sheet by an investigator 
blinded to the experimental protocol which, were then scanned into a PC running 
SigmaScan Pro 5 (Hounslow, UK). Areas (in pixels) identified as being infarcted, at 
risk of infarction or normally perfused were calculated separately. The area of normal 
perfusion was stained blue by the Evan’s blue dye. Infarct size was the area unstained 
by both Evan’s blue and triphenyltetrazolium chloride. The area at risk was the area 
stained red with triphenyltetrazolium chloride but not blue (Evan’s blue dye). Infarct 
size is expressed as a percentage of the area at risk. Figure 5.3 shows a control heart 
stained in this manner.
Area at risk Infarct Area of marked perfusion
(red) (white) (dark blue)
Figure 5.3 Picture showing a typical example o f a stained heart.
5.21 Agonist Studies
Hearts were randomly assigned to receive the cannabinoid vehicle, Tocrisolve™ 100 (a 
vehicle of 1:4 soya oiliwater mixture emulsified with poloxamer FI 88), or one of the
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following cannabinoid agonists (IjiM): anandamide, methanandamide,
arachidonlycyclopropylamide (ACPA), JWH-133 or a combination of ACPA and JWH- 
133 (lpM each). Cannabinoid agonists or Tocrisolve™ 100 vehicle were infused at a 
flow rate controlled to be 10% of coronary flow.
5.22 Antagonist studies
Where used, antagonists were present in the perfusate throughout the protocol. 
Antagonists were prepared in dimethyl sulfoxide (DMSO) as a ImM stock solution 
before being added to the perfusate (final concentration 1 pM).
Hearts were randomly assigned to one of four groups. The first consisted of the 
antagonist vehicle DMSO (0.01% vol.vol"1). The second group was treated with 
SR141716A the third group with SR144528 and the fourth group with capsazepine.
5.3 Drug preparation
The cannabinoid agonists, anandamide, methanandamide, ACPA, and JWH-133 (Tocris 
Cookson Ltd, Bristol, UK) obtained as solutions of 5mg/ml dissolved in Tocrisolve™ 
100 were diluted in Krebs bicarbonate solution to a concentration of 10'5M so that when 
infused at a rate controlled to be 10% of coronary flow a final concentration of lpM 
was obtained. The cannabinoid agonist vehicle Tocrisolve™ 100 was diluted in Krebs 
bicarbonate to give a 0.07% vol.vol'1 solution that when infused at 10% of coronary 
flow a final concentration of 0.007% vol.vol'1 was obtained. SR141617A and 
SRI44528 (gifts from Dr Barth of Sanof-Aventis, Montpellier, France) and capsazepine
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(Sigma, Gillingham, UK) were prepared in DMSO (Fisher Scientific, Leicestershire, 
UK) as ImM stock solutions and added to the perfusate (final concentration was 1 pM).
5.4 Statistical analysis
All data are expressed as the mean ± SEM of n experiments. Unpaired data were 
compared using an unpaired Student’s t-test. Multiple comparisons against a single 
control were made using analysis of variance (ANOVA) followed by Dunnet’s post hoc 
test (GraphPad InStat 3.0, California, USA). ANOVA with repeated measures was used 
to compare time course data (SPSS Inc, Illinois, USA). Statistical significance was 
taken at P <0.05.
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5.5 Results
5.51 Agonists Studies
Left ventricular pressure, rate pressure product, heart rate and coronary flow did not 
significantly vary among any of the agonist treated groups before ischaemia (Table 5.1).
In vehicle treated (Tocrisolve™ 100) control hearts, left ventricular pressure recovered 
incompletely during reperfusion recovering to a maximum of 90 ± 4% of pre-ischaemia 
values after 10 minutes of reperfusion. Thereafter left ventricular developed pressure 
steadily declined until the end of reperfusion such that by the end of reperfusion the 
values were 51 ± 4% of pre-ischaemic values (Figure 5.4a and Table 5.1). Recovery of 
coronary flow during reperfusion was also incomplete reaching a maximum (77 ± 7% of 
pre-ischaemic values) after 10 minutes of reperfusion, declining to 43 ± 7% of pre- 
ischaemic values by the end of reperfusion (Figure 5.4a and Table 5.1). Heart rate 
declined steadily over the experimental period to 79 ± 6% of pre-ischaemic values 
(Figure 5.4b and Table 5.1). Recovery of rate pressure product was also incomplete 
reaching a maximum of 78 ± 7% of pre-ischaemic values after 10 minutes of 
reperfusion, then declining to 41 ± 5% of pre-ischaemic values by the end of 
reperfusion (Figure 5.4b and Table 5.1). The area at risk was 30 ± 1% of the whole 
heart with infarct size, measured at the end of reperfusion at 28 ± 3% of the area at risk 
(Figure 5.5 and Table 5.1).
None of the cannabinoid agonists used in the study had a significant effect on the 
recoveries of left ventricular pressure, rate pressure product or coronary flow compared 
to control hearts (Figures 5.4a and 5.4b and Table 5.1). However, infarct size was
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significantly reduced by the presence of methanandamide (10 ± 5% of the area at risk 
where the area at risk was 32 ± 3% of the whole heart) compared to hearts which 
received vehicle. Infarct sizes in hearts treated with anandamide (23 ± 6% of the area at 
risk where the area at risk was 31 ± 2% of the whole heart, Figure 5.5), ACPA (35 ±3% 
of the area at risk, where the area at risk was 27 ± 3% of the whole heart) or JWH-133 
(24 ± 3% of the area at risk, where the area at risk was 30 ± 2% of the whole heart) 
individually or in combination were not significantly different from those obtained in 
vehicle control hearts (Figure 5.5 and Table 5.1). However ACPA and JWH-133 in 
combination were significantly different from those obtained in vehicle control hearts 
(51 ± 4% of the area at risk where the area at risk was 23 ± 1% of the whole heart; 
Figure 5.5 and Table 5.1).
5.52 Antagonist studies
None of the antagonists used had a significant effect on left ventricular pressure, 
coronary flow, heart rate or rate pressure product before ischaemia (Table 5.2).
In vehicle treated control hearts with 0.01% vol.vol'1 DMSO (antagonist vehicle) 
present, recovery of left ventricular pressure was incomplete reaching a maximum of 75 
± 6% of pre-ischaemic values after 10 minutes of reperfusion then falling to 42 ± 6% of 
pre-ischaemic values by the end of reperfusion (Figure 5.6 and Table 5.2). Coronary 
flow was impaired during reperfusion recovering to a maximum of 56 ± 7% of pre- 
ischaemic values after 10 minutes of reperfusion then falling to 33 ± 8% of pre- 
ischaemic values by the end of reperfusion (Figure 5.6 and Table 5.2). Rate pressure 
product recovered incompletely during reperfusion recovering to a maximum of 59 ±
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7% of pre-ischaemic values after 10 minutes of reperfusion, then declining until at the 
end of reperfusion the values were 29 ± 6% of pre-ischaemic values (Figure 5.6 and 
Table 5.2). Measured at the end of reperfusion, 30 ± 6% of the area at risk was 
infarcted where the area at risk was 33 ± 5% of the whole heart (Figure 5.6 and Table 
5.2).
Infusion of methanandamide in the presence of 0.01% vol.vol'1 DMSO had no 
significant effect on the recovery of left ventricular pressure, rate pressure product or 
coronary flow during reperfusion compared to vehicle control hearts (Figure 5.6 and 
Table 5.2). However infarct size, measured at the end of reperfusion, was significantly 
reduced to 11 ± 3% of the area at risk where the area at risk was 48 ± 5% of the whole 
heart (Figure 5.6 and Table 5.2).
No parameters of contractile function, area at risk or infarct size significantly varied 
between vehicle-treated hearts in the presence of 0.01% vol.vol'1 DMSO compared to 
hearts treated with SR141716A (lpM, Figure 5.7), SR144528 (lpM, Figure 5.8) or 
capsazepine (lpM, Figure 5.9).
Recoveries of left ventricular developed pressure, rate pressure product and coronary 
flow during reperfusion in hearts treated with methanandamide were not significantly 
affected by the presence of SR141617A, SR144528 or capsazepine when compared to 
SR141617A, SR144528 or capsazepine alone (Figures 5.7-5.9 and Table 5.2). 
However, the infarct size reduction observed when methanandamide was infused alone
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was lost in the presence of SR141617A and SRI44528 but not in the presence of 
capsazepine (Figure 5.9).
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Table 5.1 Cardiac function and area at risk o f infarction in hearts treated with cannabinoid
agonists. Times correspond to pre-drug (10 min), pre-ischaemic (15 min) and the time at the end of 
reperfusion (115 minutes).
Perfusion
Time
(min)
n LVDP
(mmHg)
CF
(ml.min1)
BPM % AAR
Tocrisolve1M 100 10 109±10 12±1 287±12
15 8 105±8 11±1 272±14 30±1
115 52±4 5±1 217±22
Anandamide 10 102±4 14±1 255±9
(lpM) 15 9 104±4 14±1 246±8 31±2
115 61±5 5±1 163±21
Methanandamide 10 105±12 13±1 245±8
(lpM) 15 7 106±13 12±1 238±12 32±3
115 46±9 4±1 110±45
ACPA 10 117±8 13±1 252±10
(lpM) 15 7 118±7 13±1 243±13 27±3
115 60±13 6±1 191±8
JWH-133 10 97±11 11±1 259±8
(lpM) 15 7 99±11 10±1 248±5 30±2
115 75±9 4±0 208±11
ACPA + JWH-133 10 105±10 11±1 263±12
(lpM each) 15 8 107±11 11±1 251±12 23±1
115 72±9 6±1 182±11
LVDP = left ventricular developed pressure, CF = coronary flow and BPM = beats per minute. Absolute 
values are given as mean ± s.e.m. with n the number o f hearts in the group.
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Table 5.2 Cardiac junction and area at risk o f infarction in hearts treated with cannabinoid
agonists and in the presence o f the cannabinoid antagonists. Times correspond to pre-drug (10 min), 
pre-ischaemic (15 min) and the time at the end o f reperfusion (115 minutes).
Perfusion
Time
(min)
n LVDP
(mmHg)
CF
(ml.min'1)
BPM % AAR
10 lOlilO 14±1 266i6
Tocrisolve™ 15 6 99±12 14±1 260i6 33i5
100 115 44±11 5±1 177il3
mAEA 10 110±8 15±1 267il5
(ljuM) 15 7 103±8 14±1 261il5 48i5
115 37±5 3±2 114i25
SR141716A 10 90±12 13±1 256il3
(lpM) 15 7 93±12 12±1 248il3 29i3
115 57±7 6±1 175il3
SR141716A + 10 107±7 11±1 259ill
mAEA (lpM) 15 10 112i8 11±1 241il0 27i3
115 56±10 5±1 172il9
SR144528 10 94±16 14±1 278il2
(lpM) 15 6 92±15 14±1 278ill 29i4
115 48±13 7±1 196i25
SRI44528 + 10 118il4 M il 274il0
mAEA (lfiM) 15 6 118±13 13±1 271il3 30i2
115 69±8 5 il 141i28
Capsazepine 10 124il3 M il 273i7
(lpM) 15 7 120il4 M il 258i6 30i2
115 54±12 5 il 194il9
Capsazepine 10 112±13 15i2 288il2
+ mAEA 15 7 110±13 15i2 275il3 27il
(ImM) 115 47±8 5i2 140i25
LVDP = left ventricular developed pressure, CF = coronary flow, BPM = beats per minute and mAEA -  
methanandamide . Absolute values are given as mean ± s.e.m. with n the number o f hearts in the group.
I l l
B150-i
a>
g  100-
>  50-
25 50 75 100 1250-25
Time (min)
20-,
100o 25 50 75-25
150-,
100 -
50-
-25 0 25 50 75 100 125
D
Time (min)
2 0 - i
1 0 -
-25 0 25 50 75 100
Time (min) Time (min)
Figure 5.4a Left ventricular developed pressure (LVDP, panels A and B) and coronary flow (CF, 
panels C and D) for hearts treated with Tocrisolve™ 100 (O, n = 8) or lpM anandamide (0, n = 9), 
lpM methanandamide (V , n = 7), lpM ACPA (M, n = 8) ,lpM JWH-133 (0 ,n  = 7), and a combination 
of lpM ACPA and lpM JWH-133 (+,n= 8) . To aid comparison the same control group appears in all 
panels. LVDP, RPP and CF did not significantly vary among any of the experimental groups (ANOVA 
with repeated measures of analysis).
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Figure 5.4b Heart rate (BPM, panels A and B) and rate pressure product (RPP, panels C and D) 
for hearts treated with Tocrisolve™ 100 (O, n = 13) or lpM anandamide (0, n = 7), lpM  
methanandamide fW, n = 6), lpM ACPA (U, n = 6) ,1/jM JWH-133 (O, n = 8), and a combination o f 
lpM ACPA and lpM JWH-133 (0, n = 9) . To aid comparison the same control group appears in all 
panels. LVDP, RPP and CF did not significantly vary among any o f the experimental groups (ANOVA 
with repeated measures of analysis).
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Figure 5.5 Infarct sizes for hearts treated with Tocrisolve™ 100 (n = 8) or lpM anandamide (n =
9), lfiM methanandamide (n = 7), lpM ACPA (n = 7), IfjM JWH-133 (n = 7) and a combination of lfjM 
ACPA and 1jjM JWH-133 (n = 10). * = P<0.05 vs. vehicle (ANOVA supported by Dunnett’s post hoc 
test).
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Figure 5.6 Left ventricular developed pressure (LVDP), coronary flow (CF), rate pressure product
(RPP), heart rate (HR) and infarct size for hearts treated with Tocrisolve™ 100 (vehicle, O, n = 6) or 
lpM methanandamide (mAEA, M, n = 7) in the presence of 0.01% DMSO. * = P<0.05 vs. vehicle 
(Student’s t-test was used to analyse the data).
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Figure 5.7 Left ventricular developed pressure (LVDP), coronary flow (CF), rate pressure product 
(RPP), heart rate (HR) and infarct size for hearts treated with Tocrisolve™ 100 (vehicle, V, n = 7) or 
lfjM methanandamide (mAEA, T , n = 10) in the presence of lpM SR141716A (SR6). There were no 
significant differences in recoveries o f coronary flow, left ventricular developed pressure, rate pressure 
product and heart rate among any o f the factors or in infarct size. * = P<0.05 vs. vehicle (Student’s t- 
test was used to analyse the data).
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Figure 5.8 Left ventricular developed pressure (LVDP), coronary flow (CF), rate pressure product
(RPP), heart rate (HR) and infarct size for hearts treated with Tocrisolve™ 100 (vehicle, A , n = 6) or 
lpM methanandamide (mAEA, A, n = 6) in the presence of 1/jM  SR144528 (SR8). There were no 
significant differences in recoveries o f coronary flow, left ventricular developed pressure, rate pressure 
product and heart rate among any of the factors or in infarct size (Student’s t-test was used to analyse the 
data).
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Figure 5.9 Left ventricular developed pressure (LVDP), coronary flow (CF), rate pressure product 
(RPP), heart rate (HR) and infarct size for hearts treated with Tocrisolve™ 100 (vehicle, O.n — 7) or 
lpM methanandamide (mAEA, 0, n = 7) in the presence o f in the presence of lpM capsazepine. * = 
P<0.05 vs. vehicle (Student’s t-test was used to analyse the data).
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5.6 Discussion
This is the first study to demonstrate that cannabinoids can reduce infarct size when 
delivered at a clinically relevant time point. Although previous studies have 
demonstrated that cannabinoids are cardioprotective (Joyeux et al., 2002; Lagneux & 
Lamontagne, 2001; Lepicier et al., 2003), this is the first where cannabinoids 
administered after the onset of ischaemia have been shown to reduce infarct size. This 
is important as it demonstrates that the mechanism of protection is independent of 
preconditioning.
The main difference between this and the previous findings in Chapter 4 is that 
anandamide did not reduce infarct size. The major difference between anandamide and 
methanandamide is that methanandamide is non-hydrolysable and therefore is not 
broken down when taken up into cells. When anandamide is broken down the diffusion 
gradient by which anandamide is taken up into the cell does not slow down, however, 
methanandamide is not broken down and therefore the concentration gradient is 
overcome and consequently methanandamide is left in contact with the tissue for a 
longer period of time than anandamide allowing it time to protect the tissue from 
damage.
There are two cannabinoid receptors that have been identified and cloned, namely CBi 
(Matsuda et al, 1990) and the CB2 receptor (Munro et al., 1993). Methanandamide, is a 
relatively selective agonist for the CBi receptor (Mechoulam et al., 1998). Therefore it 
would appear that the infarct limiting actions of methanandamide are as a result of the 
activation of the CBi receptor. However, the selective CB2 antagonist, SRI44528 as
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well as SR141716A (selective CBi antagonist) blocked the infarct-limiting response to 
methanandamide. There are two explanations for this, firstly the infarct limiting action 
of methanandamide requires both CBi and CB2 receptors to be co-stimulated so that if 
one was blocked the cardioprotective response would be lost and secondly that the 
response to methanandamide is mediated by a receptor distinct form either CBi or CB2 
but which is sensitive to the two cannabinoid antagonists.
It could be inferred that the methanandamide response is a result of activation of one or 
more unidentified receptors. As with the previous chapter (Chapter 4), the findings that 
methanandamide-induced infarct limitation was blocked by the presence of SR141617A 
or SR144528 raised the possibility that co-stimulation of the CBi and CB2 receptors or 
activation of one or more novel cannabinoid sites of action by methanandamide is 
required to limit cardiac infarction associated with ischaemia-reperfusion. However, 
since neither the CBi receptor agonist, ACPA (Hillard et al., 1999) or the CB2 receptor 
agonist, JWH-133 (Pertwee, 1999) either on their own or in combination reduced 
infarction, activation of either CBi or CB2 alone, or simultaneously, does not appear to 
account for the cardioprotection afforded by methanandamide favouring the theory that 
the response is mediated at a site distinct from these receptor subtypes.
Cannabinoids are known to mediate responses via a number of different mechanisms, 
one of which is uptake and metabolism to form products of the arachidonic acid cascade 
(Ellis et al., 1995; Kozak et al., 2002). As methanandamide is a non-hydiolysable 
analogue of anandamide (Abadji et al., 1994) responses seen to methanandamide are not
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due to release of arachidonic acid metabolites formed due to the breakdown of this 
cannabinoid.
Methanandamide is known to activate TRPV1 (Malinowska et al., 2001). Therefore, it 
is possible that TRPV1 activation might be involved in the mechanism of 
cardioprotection. However, capsazepine (TRPV1 antagonist) did not block the infarct 
limiting effect of methanandamide, therefore it is unlikely that this process is mediated 
via activation of TRPV1.
The presence of a cannabinoid receptor distinct from either the CBi or CB2 receptor 
located on endothelial cells has recently been proposed (Mo et al., 2004). Anandamide 
is thought to be able to activate this receptor therefore activation of the putative 
endothelial cannabinoid receptor (Jarai et al., 1999) may play a role in the mechanism 
of methanandamide infarct size limitation due to their similarities. However, SRI44528 
abolished the response to methanandamide which indicates that the putative endothelial 
cannabinoid receptor is not involved as it is reportedly insensitive to this antagonist (Mo 
et al., 2004).
In summary, we have shown that methanandamide limits infarct size associated with 
myocardial ischaemia-reperfusion injury without affecting contractile recovery. The 
pharmacological profile of this response is the same as that previously reported for the 
cardiac responses to methanandamide’s parent compound anandamide (Ford et al., 
2002) and fails to match with any of the previously known mechanisms of cannabinoid 
action. We therefore conclude that methanandamide reduces infarct size in rat isolated
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hearts by interaction with one or more novel sites of action that might involve a new 
cannabinoid receptor subtype.
The finding that methanandamide is cardioprotective in this model demonstrates its 
potential to be used as an adjunct of thrombolysis. Unlike in the global model of 
ischaemia (Chapter 4) where agonists were administered before ischaemia, the drug 
(methanandamide) was added at a clinically relevant time point (just prior to 
reperfusion) at which thrombolytics would be introduced to break down the occluding 
clot and therefore reperfuse the ischaemic area of the heart. However, further 
investigation needs to be carried out into the in vivo effects of methanandamide in this 
situation as cannabinoids are known vasodilators and therefore could potentially have 
adverse effects such as excessive hypotension. However, it is unlikely that a patient 
would be active (i.e. walking) when the drug was administered and therefore a drop in 
blood pressure would not present a big problem.
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Chapter 6
General Discussion
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6.0 Discussion
Cannabinoids have previously been shown to have a number of effects on heart rate 
including tachycardia as a result of A9-tetrahydrocannabinoid and cannabinol treatment 
and bradycardia as the result of cannabidiol treatment in isolated hearts (Smiley et al., 
1976). However there have not been any investigations into the direct effects of 
cannabinoids on the isolated right atria. The study reported in this thesis has shown that 
cannabinoids have a direct effect on the sino-atrial node causing an increase in heart rate 
which was shown to involve an uptake and conversion pathway into products of the 
cyclooxygenase family such as prostaglandins or prostacyclins. In addition, when 
baseline heart rate was increased by a sympathomemetic, cannabinoid agonism caused 
negative chronotropy. The mechanism of this response remains unknown; however, the 
evidence suggests the involvement of the CB2 cannabinoid receptor although the 
evidence is inconclusive because the CB2 receptor selective antagonist, SR144528 was 
ineffective in blocking the negative chronotropic response.
Cannabinoids have potential therapeutic benefits over other well known 
cardioprotective agents such as adenosine because they have a minimal effect on heart 
rate. Adenosine, as with cannabinoids, can be produced as a retaliatory metabolite and 
also acts through Gi linked receptors (Mubagwa & Flameng, 2001). Adenosine has 
been shown to have a depressant effect on the sino-atrial node, with intravenous bolus 
administration causing sinus arrest (Belardinelli et aL, 1989).
Work as part of this thesis has also added further credence to that of previous studies 
implicating cannabinoids in cardioprotection (reduction in infarct size) in both a global
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and regional ischaemia model of cardiac damage. Two previous studies which 
implicated endocannabinoids in the protection against ischaemia-reperfusion injury 
reported the involvement of cannabinoids in the protection afforded by 
lipopolysaccharide treatment (Lagneux & Lamontagne, 2001) and in the limitation of 
infarction induced by heat stress preconditioning (Joyeux et al., 2002). In both studies 
SRI44528 the CB2 receptor antagonist inhibited the protective effects of the treatments 
indicating that activation of CB2 receptors are involved. CB2 receptor involvement in 
cardioprotection has also been reported in a more direct study by (Lepicier et al, 2003) 
where palmitoylethanolamide and 2-arachidonoylglycerol but not anandamide were 
shown to improve recovery and reduce infarct size in a low-flow model of global 
ischaemia. A selective CBi agonist, ACEA and a selective CB2 agonist, JWH-015 also 
limited infarction. However, the results of the Lepicier study are confusing because 
palmitoylethanolamide has no efficacy at either CBi or CB2 receptors (Felder et al., 
1995) and was shown to be devoid of any activity when administered to isolated rat 
hearts (Ford et al., 2002). Although this study did not identify the exact mechanism by 
which cannabinoids were mediating protection against damage caused by ischaemia- 
reperfusion it was able to eliminate a number of candidate receptors that do not appear 
to be involved including both the cloned cannabinoid receptors (CBi and CB2) either 
individually or in combination or TRPV1. Uptake of the cannabinoids was also ruled 
out leading to the conclusion that cannabinoids were mediating protection through a 
novel site.
Novel sites of actions of cannabinoids have previously been reported. These include a 
non-CBi, non-CB2 endothelial receptor where anandamide and methanandamide but not
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synthetic cannabinoids or A9-tetrahydrocannabinoid have been shown to be agonists and 
which is sensitive to the CBi receptor antagonist SR141617A but at a higher 
concentration than for the CBi receptor (Chaytor et al, 1999; Jarai et al, 1999; 
Mukhopadhyay et al, 2002; Wagner et al, 2001a; Wagner et al, 2001b; White et al,
2001). The inhibitory action of SR141716A was only observed in the presence of an 
intact vascular endothelium and was lost on denudation. As a result it was proposed 
that there was an endothelial site distinct from CBi and CB2 receptors but sensitive to 
SR141716A involved in the vasodilator effect of anandamide and methanandamide in 
the rat mesenteric circulation (Jarai et al, 1999). It is possible that a similar mechanism 
may account for the actions of cannabinoids in the rat coronary circulation (Ford et al,
2002). It is not believed that the endothelial receptor is responsible for the 
cardioprotection afforded in this study because the CB2 receptor antagonist SRI44528 
blocked the protective effect and it has previously been demonstrated that the 
endothelial receptor is insensitive to this antagonist (Mo et al, 2004).
A non-CBi, non-CB2 receptor on immune cells has also been proposed based on the 
finding that the analgesic effect of palmitoylethanolamide is blocked by the CB2 
antagonist SR144528, but not the CBi antagonist SR141716A (Calignano et al, 1998; 
Jaggar et al, 1998) even though palmitoylethanolamide does not bind to CB2 receptors 
(Griffin et al, 2000). This response was also not the result of TRPV1 activation 
because palmitoylethanolamide did not inhibit the capsaicin-induced pain (Calignano et 
al, 2001).
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Splice variants of CBi known as CBiA and CBiB have also been identified (Ryberg et 
al., 2005; Shire et al., 1995). Polymerase chain reaction revealed that CBi was not 
present in the heart and neither was the CBiB splice variant, however, CBiA was found 
(Ryberg et al., 2005). This verifies results in a previous study which first identified the 
CBiA variant and showed that both CBi and CBiA mRNA was present in the heart 
(Shire et al., 1995). Due to the low abundance of cDNA for both of the CBi splice 
variants it could be suggested that they do not contribute to cannabinoid pharmacology 
in different tissues. It is not believed that the splice variants are responsible for the 
cardioprotection seen or the effects on heart rate in this study because none of the 
known cannabinoid ligands of the CBi receptor including anandamide have any 
significant agonist activity at either of the variants (Ryberg et al., 2005).
In silico searching of public patent data bases has recently revealed a potentially new 
cannabinoid receptor (GPR55) that displays high affinity for endogenous, natural and 
synthetic cannabinoids (Drmota, 2004). However, it is unlikely that this orphan G- 
protein coupled receptor is responsible for mediating the responses observed in the heart 
as SR141716A acts as a GPR55 agonist (Brown et al., 2005; Brown & Wise, 2001) 
whereas responses to anandamide were antagonised in our study.
In the future investigation is required to establish the signal transduction pathways 
involved in the cardioprotective mechanism of cannabinoids (Figure 6.1). CBi 
receptors have been shown to be coupled to both phosphoinositide 3’-kinase and protein 
kinase B (Gomez del Pulgar et al., 2000). Activation of both of these proteins has been 
shown to mediate the inhibition of ischaemia reperfusion-induced cardiac apoptosis
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caused by insulin (Jonassen et al., 2001). Therefore the inhibition of apoptosis induced 
by anandamide (Maccarrone et a l , 2000b) could be the result of activation of one of 
these pathways.
Growth factor
Tyrosine kinase receptorLavedustin A
P l^ fn ase  Wortmannin
MKK
P42/44 + inase
Rapamycin
Inhibition of caspase 3
Inhibition of apoptosis 
(prosurvival)
Figure 6.1 Possible investigative pathway for the anti-apoptotic effect o f cannabinoids. 
Lavedustin A (tyrosine kinase receptor inhibitor) and wortmannin (PI3-kinase inhibitor) would be used to 
see i f  cannabinoids act upstream o f protein kinase B (PKB) and rapamycin (p70 s6-kinase inhibitor) 
would be used to investigate i f  cannabinoids affect prosurvival down stream o f PKB where P70 s6-kinase 
promotes protein synthesis and the phosphorylation o f Bad leads to the inhibition o f apoptosis. Inhibitors 
are represented by X.
In vivo work to ascertain the affect of cannabinoids on the whole body is also required. 
This is necessary because the relationship between cardiac function and blood pressure
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is complex, and an in vivo model is the only way to accurately assess drug action on 
blood pressure, cardiac output and heart rate. An in vivo model would not only 
investigate the pharmacological effects of cannabinoids but would also be used to 
demonstrate that treatments to reduce ischaemia-reperfusion injury in a more complex 
situation than that used in this study and this experimental model may also uncover any 
adverse effects cannabinoids may elicit elsewhere in the cardiovascular system which 
would knock out any beneficial effects (reduction in infarct size) seen.
Cannabinoids may have a therapeutic future in the prevention of ischaemia-reperfusion 
injury. Another endogenous cardioprotective agent is adenosine. One major problem 
with the use of adenosine is that it is a potent negative chronotrope (Shryock & 
Belardinelli, 1997) and has been shown to be able to stop the heart (Belardinelli et al., 
1989), this is of special importance when patients already have compromised cardiac 
function. Cannabinoids have not been shown to have such a profound effect on heart 
rate and could therefore be used in those patients with compromised cardiac function. 
However, cannabinoids are known vasodilators and could potentially cause an 
unwanted decrease in blood pressure. Uptake inhibitors could then be used in 
conjunction with the cannabinoid to prevent this occurring. Although more 
experimental work is required I believe that cannabinoids have the potential as future 
therapeutic drugs for the treatment of ischaemia-reperfusion injury.
Not only could cannabinoids be a potential treatment for ischaemia-reperfusion injury 
but they could also be used for the clinical management of cardiogenic shock. 
Activation of vascular CBi receptors has been shown to contribute to severe
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hypotension after experimental myocardial infarction and the selective CBi antagonist 
prevented post-myocardial infarction hypotension although this aggravated early 
endothelial dysfunction and worsened mortality. Therefore targeting cannabinoid 
biosynthesis, specific receptors and biological degradation systems may become a new 
strategy for the clinical management of cardiogenic shock (Wagner et al., 2001a).
It is obvious that we are at the very beginning in our understanding of cannabinoid 
pharmacology and it is apparent through all the work in this thesis that there are 
responses in the heart that cannot be explained by activation of one or more of the 
currently characterised pathways. Until the full range of cannabinoid-related receptors 
is determined, problems related to attributing functions to cannabinoid molecules based 
on pharmacology will remain. It is equally clear that cannabinoid-based therapeutics 
may be of benefit in numerous clinical settings making the study of cannabinoids 
pharmacology a clear priority.
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